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Abstract 
Glycosylation is one of the most common post-translational modifications of proteins that 
affects their biological activity, solubility, and half-life. Therefore, its characterization is of 
great interest in proteomic, particularly from a diagnostic and therapeutic point of view. 
However, the number and type of glycosylation sites, the degree of site occupancy and the 
different possible structures of glycans can lead to a very large number of isoforms for a given 
protein, called glycoforms. The identification of these glycoforms constitutes an important 
analytical challenge. Indeed, to attempt to characterize all of them, it is necessary to develop 
efficient separation methods associated with a sensitive and informative detection mode, such 
as mass spectrometry (MS). Most analytical methods are based on bottom-up proteomics, 
which consists in the analysis of the protein at the glycopeptides level after its digestion. Even 
if this approach provides essential information, including the localization and composition of 
glycans on the protein, it is also characterized by a loss of information on macro-
heterogeneity, i.e. the nature of the glycans present on a given glycoform. The analysis of 
glycoforms at the intact level can overcome this disadvantage. The aim of this review is to 
detail the state-of-the art of separation methods that can be easily hyphenated with MS for the 
characterization of protein glycosylation at the intact level. The different electrophoretic and 
chromatographic approaches are discussed in detail. The miniaturization of these separation 
methods is also discussed with their potential applications. While the first studies focused on 
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the development and optimization of the separation step to achieve high resolution between 
isoforms, the recent ones are much more application-oriented, such as clinical diagnosis, 
quality control, and glycoprotein monitoring in formulations or biological samples.  
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hydrophobic interaction chromatography; HRMS, high-resolution mass spectrometry; ICR, 
ion cyclotron resonance; IFN-β, interferon-β-1a; mAb, monoclonal antibody; Man, mannose; 
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translational modifications; Q, quadrupole; RNase B, ribonuclease B; Ser, serine; Tf, 
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1. Introduction 
The study of glycoproteins is a rapidly growing field, which is not surprising since 
approximately 70% of human proteins are glycosylated [1,2] and protein properties mainly 
depend on their glycosylation such as stability, cell-cell communication, localization, half-
life, and activity [2-5]. The impact of protein glycosylation is evident in diseases related to its 
disorders [6], such as autoimmune diseases [7,8], Alzheimer’s disease [9], cancers [10-12], or 
genetic defects [13,14]. This is why the glycosylation state of some proteins of interest in 
biological fluids may be disease biomarkers. Moreover, many glycoproteins have been 
approved as biopharmaceutical drugs, such as erythropoietin (EPO) and monoclonal 
antibodies (mAbs). Since their glycosylation state affects their stability, solubility, and 
clearance, its characterization is essential during their development (discovery, preclinical, 
and clinical steps), production, storage, and delivery [4,5]. Many steps are therefore 
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concerned, such as clone selection, pharmacokinetic and pharmacodynamic studies, in-
process control, quality control of the final product, consistency from lot to lot in glycan 
composition, sialic acid content, glycan profiles, or glycan sequences. However, the 
characterization of protein glycosylation leads to huge analytical challenges, as glycosylation 
is one of the most complex post-translational modifications (PTMs).  
Two types of glycans can be linked to proteins: N- and O-linked glycans (Figure 1). N-
glycosylation corresponds to the attachment of a glycan to the protein by an asparagine (Asn). 
Due to their common biosynthesis pathway [15], all N-glycans have a common structure 
composed of 2 GlcNAc and 3 mannoses (Man) and can be classified in 3 groups: (i) high-
mannose, containing only two GlcNAc and a variable number of Man, (ii) complex, 
composed of different monosaccharides in addition to the common structure, and (iii) hybrid, 
combining both high-mannose and complex-type species. Complex N-glycans are the main 
forms in humans. With regard to O-glycosylation, the most common is initiated by the 
addition of a single monosaccharide GlcNAc (O-GlcAcylation) or GalNAc (mucin type 
glycosylation) to Ser or Thr of proteins. These O-linked glycans have no common structure 
and their size can vary, ranging from a single monosaccharide residue to extended chains, and 
can include a large number of different monosaccharides [16].  
For each glycoprotein, potential N- or O-glycosylation sites may be occupied in varying 
proportions and different glycans can be present at a given glycosylation site, resulting in 
micro-heterogeneity for each site. In addition, glycoproteins may also have other types of 
PTMs including acetylation, phosphorylation, methylation, etc. Consequently, glycosylation 
and other PTMs lead to a large number of isoforms for a given protein, with different 
molecular weights and concentrations.  
The most commonly used approach to characterize protein glycosylation is the bottom-up 
one, based on the analysis of glycopeptides resulting from protein digestion, which allows the 
identification and localization of the glycans on the protein [5,17-22]. This site-specific 
information is useful for assessing the micro-heterogeneity of each glycosylation site and for 
confirming the possible presence of other PTMs. Nevertheless, this requires different pre-
treatment steps, such as often preliminary reduction and alkylation steps, an efficient 
enzymatic digestion of the protein, and purification and/or enrichment methods of 
glycopeptides prior to liquid chromatography (LC) or capillary electrophoresis (CE)-mass 
spectrometry (MS) analysis.  
 
4 
 
Figure 1: Representation of (A) N- and (B) O-glycans. 
 
Another way to study protein glycosylation is to analyze glycans released by glycoproteins or 
glycopeptides [5,19,21-25]. This approach allows the determination of the intrinsic structural 
heterogeneity of glycans resulting from branching, isomerism, and linkage position between 
different monosaccharides. As for the glycopeptide analysis, a reduction/alkylation step 
followed by enzymatic digestion or chemical reaction is usually necessary to release the 
glycans [26]. Several purification/extraction steps can be carried out to facilitate the 
identification and quantitation of glycans by removing peptides, proteins, salts, and some 
other molecules added during the sample pre-treatment [27]. A derivatization step is often 
performed to improve both their separation in LC or CE and detection by fluorescence or MS.  
The analysis of protein glycosylation can also be performed at the intact level [5,22,28-30], 
leading to different and complementary information compared to the two approaches 
described above. For example, the analysis of the protein isoforms at the intact level is the 
only way to correlate an isoform with its different PTMs and determine the total number of 
isoforms and their relative abundances. This is very relevant when some isoforms are 
biomarkers. Moreover, the two previous approaches require one or more enzymatic digestion 
steps, sometimes combined with enrichment and/or derivatization steps, thus leading to a long 
and costly analytical protocol. In return, the intact approach does not require complex sample 
pretreatment, therefore is faster and cheaper, and prevents from modifications induced by 
sample handling. For all these reasons, the characterization of glycoproteins at the intact level 
has increased rapidly over the past decade.  
Complex
Hybrid
High mannose
Mannose (Man)
Galactose (Gal)
Acid N-acetylneuraminic (NeuAc)
N-acetylglucosamine (GlcNAc)
Fucose (Fuc)
A B
Asn Thr/Ser
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However, the main challenge in this case is to achieve an efficient separation of isoforms, 
which may be difficult due to their structural similarities, especially for proteins with different 
glycosylation sites leading to a high number of glycoforms. LC and CE are both high-
performance separation methods that can help to achieve this objective. They are often 
hyphenated to MS owing to an electrospray ionization (ESI) source, thus providing 
sensitivity, selectivity, and information on glycoform identity [5,22]. The hyphenation of the 
separation step with MS dramatically improves the efficiency of the ionization step and leads 
to simplified mass spectra, even when using high-resolution MS (HRMS). With regard to 
literature, some reviews have already been published on CE and LC coupled with MS for the 
analysis of intact proteins [28,31-35], but they have not specifically focused on characterizing 
their glycosylation. Therefore, we propose, in this review, to discuss in detail the potential of 
CE and LC hyphenated to mass spectrometry for the characterization of the glycosylation of 
proteins, analyzing them in their intact form. Approaches used to reduce the size of large 
proteins, such as the middle-up for example, to obtain fragments before analysis will not be 
discussed here, as they have already been presented in other reviews [17,21,22]. Two types of 
applications are concerned, the analysis of (i) pharmaceutical preparations containing the 
protein at a high concentration in a quite simple solution and (ii) biological samples of much 
greater complexity with potentially low concentrations of the target glycoprotein. This second 
application requires a careful sample handling before separation and detection steps, as 
already discussed in some reviews [5,19,20,36].  
 
2. Capillary Electrophoresis  
Different CE modes are regularly used for the analysis of intact proteins, such as capillary 
zone electrophoresis (CZE), capillary isoelectric focusing (CIEF) or capillary gel 
electrophoresis (CGE). CGE can separate glycoforms, because glycans modify the mobility of 
the glycoform in gel electrophoresis with their mass but also with their charge since the 
sodium dodecyl sulfate molecules do not interact with them. Nevertheless, CGE is not 
compatible for a direct coupling with MS, preventing further characterization of isoforms. 
Therefore, only CZE and CIEF are addressed in this review for their contribution to the 
glycosylation characterization. 
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2.1 Capillary zone electrophoresis 
Historically, CZE is the most used method for the separation of intact proteins and its 
potential has already been widely described in the literature [28,31,33]. It is characterized by 
high-efficiencies, especially for proteins as they have a low diffusion coefficient, can use 
native aqueous conditions, preventing denaturation or change in conformation due to a 
stationary phase or solvent, and can separate protein isoforms according to their charge-to-
size ratio. CZE can also be easily hyphenated with MS via an ESI source when a volatile 
background electrolyte (BGE) is used. This hyphenation allows the characterization and 
identification of isoforms, particularly with HRMS analyzers [32,37]. 
Focusing on glycoproteins, CZE-MS was used for their analysis at the intact level to 
characterize their glycosylation (Table 1), either for glycoprofiling and fingerprinting 
purposes, or for identification in clinical diagnosis, quality control or monitoring in 
formulations. More than 30 papers were published, one-third dealing with EPO (3 N- and 1 
O-glycosylation sites) and two-thirds with other glycoproteins such as ribonuclease B (RNase 
B, 1 N-glycosylation site), Transferrin (Tf, 2 N-glycosylation sites), mAbs (2 N-glycosylation 
sites), α1-acid glycoprotein (AGP, 5 N-glycosylation sites), human chorionic gonadotropin 
(hCG , 4 N- and 4 O-glycosylation sites) or interferon-β-1a (IFN-β, 1 N-glycosylation site).  
 
2.1.1 Sample considerations 
Most analyses used protein concentrations of some mg/ml. Some authors increased the 
injection volume to 2.7 or 4% of the capillary volume, but this has negatively affected the 
separation resolution [61,62]. Indeed, as large injection volumes in CZE induce a dramatic 
band broadening, high concentrations are required to inject sufficient sample amounts. 
Nevertheless, they may induce the formation of aggregates [44]. It is worthwhile to notice that 
a large number of isoforms induces a decrease in sensitivity for a given isoform. As an 
example, more than 100 isoforms were detected for EPO, with signals varying by 2 to 3 
orders of magnitude, with a sensitivity in the femtomol range [47]. 
When pharmaceutical formulations are analyzed, the glycoprotein concentration can easily 
reach the mg/ml range, often after a simple centrifugal filtration step which also eliminates 
salts and excipients. However, if the targeted protein is in biological samples, its 
concentration may be very low and it may be among other highly concentrated proteins. As an 
example, the concentration of endogenous EPO is in the ng/l range in human urines and about 
10 ng/l in serum. In that case, a pretreatment step must be optimized before analysis. CZE- 
MS can be very useful for characterizing purified samples with different methods to select 
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one that reduces sample preparation time, has a high extraction yield, and minimizes chemical 
modifications and, therefore, changes in isoform pattern. For example, two methods for 
purifying AGP from human serum were evaluated, in particular with regard to the potential 
AGP desialylation due to the use of acidic conditions [41]. One was based on the use of an 
acidic reagent for precipitation that was neutralized immediately after precipitation and before 
immunoextraction. In the second one, the acidic precipitation was skipped before the 
immunoextraction step and led to higher yields.  
 
2.1.2 Capillary coating 
After sample injection, the best possible separation must be obtained in order to favor as 
much as possible the ionization of all isoforms, especially the minority ones, which will then 
improve the signal intensity of ions and the quality of their MS spectrum. It is often necessary 
to coat the capillary to both limit protein adsorption and control electroosmotic flow (EOF) as 
shown in Table 1. For the coupling of CZE with MS, a dynamic coating requiring the constant 
presence of a non-volatile coating agent in the BGE is excluded, despite its simplicity and 
stability. A statically adsorbed coating may be used, resulting from successive percolation(s) 
in the capillary of one or more polymer solutions prior to the analysis, when the capillary 
outlet is out of the ESI source, leading to a semi-permanent coating. A permanent, i. e. 
covalently immobilized, coating can also be used, avoiding frequent recoating and potential 
contamination of the MS source. Several reviews describing these different types of coating 
are available [64,65]. 
As it can be seen in Table 1, three approaches are used: 
- a cationic coating, giving an anodic EOF (written A in the EOF column), with an 
acidic BGE. Isoforms are positively-charged, favoring their electrostatic repulsion 
with the positively-charged capillary surface. EOF and analyte mobility are in 
opposite directions, which may increase resolution but also analysis time if EOF is not 
too high. This is the most common approach. 
- a neutral coating suppressing EOF (written 0 in the EOF column) with an acidic BGE. 
Isoforms are positively-charged and resolution depends only on their electrophoretic 
mobility difference.  
- an anionic coating, leading to a cathodic EOF (written C in the EOF column), with a 
basic BGE. Isoforms are negatively-charged, favoring their electrostatic repulsion with 
the negatively-charged capillary surface. EOF and analyte mobility are in opposite 
8 
directions. This is the less used configuration, because acidic BGE is often preferred to 
improve the MS ionization in positive mode. 
For the first approach, the first impressive results showing the analysis of many isoforms in 
CZE-ESI-MS were obtained with EPO [45,47] using a cationic Polybrene (PB)-based coating 
combined with an acidic BGE. Even if they are some exceptions such as a strong adsorption 
observed for the Tf glycoforms, regardless of cationic polyethylenimine (PEI) concentration, 
coating procedure, BGE composition, and pH [62], these conditions generally provide high 
efficiencies, such as those obtained for IFN-β between 350,000 and 450,000, allowing the 
resolution of isobaric positional isomers of a single sialic acid on biantennary glycan, and the 
detection and quantification of 138 isoforms [58]. Another cationic polymer containing an 
amine (LA 113) was also reported for capillary coating and the analysis of VGEF165 isoforms 
[63]. A multilayer coating based on PB-dextran sulfate (DS)-PB was used to improve EOF 
reproducibility and coating stability [57,66].  
In different studies, cationic and neutral coatings were compared (see Table1). For example, a 
cationic PB coating was compared to a polyacrylamide (PA)-based coating at acidic pH [38]. 
For both fetuin and AGP proteins, the separation of the main sialoforms was considerably 
improved with the suppression of EOF. Indeed, in this case, the CZE separation results from 
the isoform electrophoretic mobilities, providing a better separation resolution within a 
relatively acceptable analysis time. In addition, partially resolved peaks appeared, 
corresponding to glycoforms with the same sialic acid number but with an additional 
HexHexNAc. As expected, the increase in resolution improved the quality of the mass spectra 
and enhanced sensitivity. A similar study carried out with EPO came to the same conclusions 
[48].  
A more detailed study was performed by Neusüβ and coll. to compare coatings based on PA, 
UltraTrol High Reverse (HR), underivatized PAA, N,N-dimethylacrylamide-ethylpyrrolidine 
methacrylate, or PEI, for the separation of EPO isoforms and a mixture of small and medium 
size proteins (<33 kDa) [52]. The best resolution was obtained with the neutral coatings. 
Gimenez et al. also compared neutral PA and anionic UltraTrol HR coatings for the analysis 
of EPO and novel erythropoiesis-stimulating protein (NESP) [49]. If, once again, the neutral 
coating gave a higher resolution than the cationic one, but also a longer analysis time, the 
reproducibility studies demonstrated a lack of stability and a bleeding of the PA coating, 
resulting in a dramatic loss of sensitivity in MS and the presence of interfering peaks in the 
spectra. The cationic coating had enhanced stability. It is worthwhile to notice that to improve 
the neutral coating stability, it has to be done every 5 to 10 runs and requires removing the 
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capillary from the CE-ESI-MS interface to avoid contamination of the ESI source [51,52]. A 
rinsing step with 3 M HCl before coating also helps to maintain reproducible migration times.  
Therefore, it appears in the studies presented in Table 1 that most often the second approach 
involving an acidic BGE plus a neutral coating that suppresses EOF led to higher resolution 
than the first approach with a cationic coating. Although the EOF and analyte mobility are in 
opposite directions, which should increase resolution, this was not observed because the EOF 
was too high. Indeed, in another study with a cationic coating with an acrylamide-pyrrolidine 
methacrylate copolymer generating a moderate EOF, a better separation of AGP isoforms was 
obtained and in less time than with a neutral coating [41].  
Recently, a new neutral coating (Neutral OptiMS) was evaluated for mAb characterization 
[59]. It consists of a first hydrophobic layer to protect siloxanes from hydrolysis and a second 
layer of polyacrylamide providing a hydrophilic surface to improve its stability. Therefore, 
this criterion must also be taken into account when choosing the most appropriate coating. 
This also depends on the objective, i.e. to characterize the greatest number of glycoforms, 
even if the analysis time will be high, or a fast analysis at the expense of the separation 
resolution [48,53,54].  
In the third approach, an anionic coating and a BGE with a pH superior to the pI values of the 
protein glycoforms are preferred. As an example, a PB coating and a wide range of pH and 
ionic strength values did not give successful separation of Tf glycoforms, unlike an anionic 
coating and a BGE composed of 25 mM ammonium acetate at pH 8.5 [62]. The anionic 
coating was obtained with a first layer of PB followed by a second DS layer leading to a pH-
independent cathodic EOF.   
Another criterion for selecting the nature of the coating may be the objective of analyzing the 
protein in denaturing or native conditions. Indeed, the strongly acidic BGEs that may also 
contain solvent can induce protein denaturation. To analyze the protein in native conditions, a 
BGE with a physiological pH is required. Therefore, Karger and coll. selected a cationic 
coating for the characterization of mAbs in denaturing conditions and a neutral one when 
native conditions were used [60]. Nevertheless, the separation of the 2x-glycosylated mAb 
(with glycans present on both Fc/2 domains), 1x-glycosylated mAb (with glycans present on 
one of the two Fc/2 domains), and a glycosylated mAb was only observed with the BGE 
composed of 10% isopropanol in 2% FA, i. e. in denaturing conditions. 
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2.1.3 Other CZE parameters 
In addition to the capillary coating, the BGE composition must also be optimized, i. e. the pH, 
ionic strength, nature and content of an additive and/or solvent, which all affect the ionization 
state of isoforms, their mobility, solubility, and potential adsorption on the capillary wall. 
Moreover, the BGE must be volatile. It impacts the separation (resolution and analysis time), 
but also the ESI ionization, so the sensitivity of the final method. An increase in the ionic 
strength of the BGE [56] or the addition of a solvent such as MeOH [45] can improve 
resolution. The generated intensity and therefore the Joule effect is also a criterion and some 
limit values are recommended with some CE-MS interfaces. Other conventional CZE 
parameters such as capillary length, voltage, and/or temperature must also be optimized in 
parallel with the BGE composition, as was done for example for the analysis of neo-
glycoproteins [66]. 
After separation in CZE, the glycoforms must be ionized for their introduction in the MS 
analyzer. This requires a volatile BGE, although in some cases, the use of non-volatile agents 
such as urea cannot always be avoided to achieve separation. For example, the separation of 
the AT isoforms required the introduction of urea at 4 M [43]. A neutral coating was thus 
necessary to completely suppress the EOF, preventing the introduction of high amounts of 
urea into the ESI source. Another option may be to carry out two-dimensional CZE-CZE-MS, 
with a four-port valve interface allowing the use of a non-volatile BGE in the first dimension 
leading to high resolution and a volatile BGE in the second dimension to favor the MS signal 
[68]. 
 
2.1.4 CE-MS interfaces 
With regard to the CE-MS interface, CE can be coupled to ESI-MS by sheathless or sheath-
liquid interfaces, as it was reviewed [31,69]. Nevertheless, Table 1 shows that by far the most 
commonly used interface for the glycoprotein characterization is the coaxial junction with a 
sheath liquid, the sheath liquid being the most important parameter affecting signal intensity 
and spray stability. It is composed of water with an organic solvent, e.g. methanol or 
isopropanol, and a low concentration of acetic acid or FA, usually between 0.1 and 1%, to 
promote ionization in positive mode. Its composition must be carefully optimized, as 
demonstrated for the ionization of Tf glycoforms, by varying the type and content of organic 
solvent (methanol and 2-propanol) and modifier (acetic and formic acids, between 0.05 and 
1%) [61]. In this case, the best results were obtained with 90% MeOH and 0.5% FA, after 
comparing the optimized water/organic solvent ratios for each solvent. Another study dealing 
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with the separation of Tf isoforms compared methanol, 2-propanol, and acetonitrile (ACN) 
and both methanol and ACN led to lower signal intensities than 2-propanol with a proportion 
of 50% [62]. A higher content of organic solvents induced unstable ESI currents, while a low 
proportion led to poor ionization. The addition of 5% of FA was necessary to ensure 
substantial ionization of the Tf isoforms. Acetic acid gave lower ionization and higher noise 
and instability, while trifluoroacetic acid (TFA) led to strong ion suppression. In another 
study, it was also observed that FA induced higher ionization, but noise in the MS spectra was 
higher than when acetic acid was used [63]. 
In some cases, a compromise must be found between separation and detection to select the 
most appropriate solvent. For the analysis of EPO isoforms, 2-propanol, methanol, and ACN 
were compared in combination with different ratios of water in the BGE [52]. Methanol had a 
similar performance to 2-propanol in terms of separation efficiency and electrospray stability, 
but led to intensities about 3 times lower comparing equal water/organic solvent ratios. A 
strong instability of the electrospray was observed with ACN.  
The sheath liquid flow-rate also affects sensitivity, which is improved as the flow-rate 
decreases. This is why, the minimum flow-rate value allowing a stable spray is often selected 
[52,61]. The nebulizer gas flow-rate can induce an aspirating effect, inducing a decrease in 
migration times [52,61]. This effect decreases with the nebulizer gas pressure, but the ion 
intensity too.  
In 2011, a sheathless CE-MS interface, called CESI, was commercialized. It was first 
evaluated for glycoform profiling by Somsen and coll. [53]. A neutral coating and a BGE with 
an acidic pH were used to favor the resolution of glycoforms of IFN-β and EPO. During the 
analysis, a pressure of 0.5 psi was applied at the capillary inlet, inducing an overall flow-rate 
of 5 nl/min to ensure a stable electrospray since a near-zero EOF was obtained. Crucial 
interfacing parameters, like dry gas flow-rate, ESI voltage, and capillary tip position plate 
distance were optimized. After optimization, more than 80 isoforms including 18 glycoforms 
were detected for IFN-β in a single CZE-MS run, and 250 isoforms including 74 glycoforms 
for EPO. A high sensitivity and a wide linearity range were reached. Indeed, assuming an 
equal ESI-MS response for all glycoforms and taking into account the injected protein 
concentration and calculated relative peak areas from extracted ions electropherograms (EIEs) 
into account, IFN-β glycoform concentrations varied between 0.53 and 946 nM (about 0.01-
20 µg/ml). Similarly, the relative intensities extend over more than 3 orders of magnitude 
from the most abundant to the least abundant glycoforms detected. This interface and a 
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neutral coating were then evaluated for mAb characterization [59,60]. Again, a small pressure 
of 0.5 or 3 psi was applied at the capillary inlet to ensure a stable electrospray.  
 
2.1.5 Performances  
With optimized BGE and coating, glycoforms varying by their sialic acids can be easily 
separated, as demonstrated for Tf [67], EPO [45,47,53], IFN-β [53] or hCG α-subunit (hCGα) 
[54]. This is illustrated in Figure 2, which shows the analysis of a drug based on recombinant 
human EPO. The EPO glycoforms are resolved over a 20-min time window (Figure 2A). 
Figure 2B shows the deconvoluted mass spectrum obtained at the apex of the peak migrating 
at 38.0 min, revealing a glycoform with a mass of 29,597 Da. Minor spectral bands with 
masses of +16 Da and +42 Da relative to the main mass indicate the presence of oxidation and 
acetylation products. A total of 74 distinct glycoforms were detected and Figure 2C1 shows 
the glycoform resolution obtained by combining the high-efficiency of CZE with HRMS. 
Focusing on the state of charge 14+ (Figure 2C2), glycoforms containing the same number of 
sialic acid residues are along diagonal rows, a difference from one sialic acid residue causing 
a migration time shift of about 2 min. The separation of isoforms in CZE is mainly oriented 
by their charge differences because they often have a similar size. However, a HexHexNAc 
unit also induced a shift in migration time for EPO (Figure 2C3), whereas this moiety should 
not be charged in the BGE used for the separation at pH 2.1, but to a lesser extent (about 0.5 
min per HexHexNAc) since a HexHexNAc contributes only to about 1% of the total mass of 
the protein. Similar results were obtained for hCGα [54] and IFN-β [53,57]. Similarly, 
isoforms of RNase B varying from only one neutral sugar, Man, were successfully separated 
[56]. This was also the case for bone morphogenetic protein-2 (BMP-2) isoforms varying 
from mannose units, but a preliminary reduction-alkylation step was mandatory [44]. 
In most of the works reported in Table 1, the figures of merit such as the repeatability of 
migration times and peak areas, LODs and LOQs, are very rarely given. The relative standard 
deviations (RSDs) of migration times and peak areas given by some authors are in agreement 
with those obtained usually in CE-MS. As an example, the intra- (n=8) and inter-day (n=11, 2 
days) precision of migration times of 8 EPO isoforms was between 1.4 and 1.9% [52]. For 
peak areas, RSDs between 6.7 and 18.0% were calculated. Nevertheless, the peak area 
repeatability may be affected by the number of charge states considered to get the extracted 
ion electropherograms, as it is also the case for calculating the LOD and LOQ values. It is 
worthwhile to notice that the definition of LOD or LOQ must be precisely defined when 
analyzing glycoforms. Indeed, it may be related to the concentration of the whole protein or a 
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single glycoform. When many glycoforms can be present, nearly 100 as an example for EPO, 
it impacts dramatically the given value. Although it is difficult to compare different MS and 
CE instruments, which can also use different capillary dimensions and injected volumes, 
values in the order of some hundreds of µg/ml were published for the total concentration of 
EPO, with a sheath-liquid interface and a quadripole-time-of-flight (qTOF) analyzer [52].  
 
 
Figure 2: Sheathless CE-MS of EPO (0.2 mg/ml) employing a neutral coated capillary. (A) 
BPE; (B) deconvoluted mass spectrum obtained in the apex of the peak migrating at 38.0 min 
(*); (C1) presentation of the electropherogram as a contour plot to show the high resolution 
obtained by combining CE with HRMS with zooms of (C2) the 14+ charge state of the 
glycoforms and (C3) the 14+ charge state of the SiA13 sialoforms. Reprinted with permission 
from [53]. 
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With a CESI interface hyphenated with a TOF and a neutral coating capillary (requiring the 
application of a pressure of 0.5 psi at the capillary inlet to ensure a stable spray), the RSDs 
(n=10) of migration times and peak areas for the main glycoforms of IFN-β were 1.9% and 
11%, respectively [53]. In repeated EPO analysis, they were 2.4% and 13% (n=6), 
respectively. The detection limit was in the picomolar-range (some tens of µg/ml). With a 
CESI interface hyphenated with an Orbitrap and a cationic PEI coating capillary, RSDs (n=4) 
of the migration times below 2% from run-to-run were obtained [58]. To compensate for 
variations in EOF, the free solution mobility of each isoform was determined and RSD values 
(n=6) less than 0.6% were observed for different capillaries over several days. 
Linearity is also a key parameter, especially when glycoforms may be present in a wide 
dynamic range for a given glycoprotein, some of them being very abundant and other being in 
the minority. A linearity of one order of magnitude was observed for EPO glycoforms, which 
is quite low but no higher concentration of EPO was available in this case [52]. 
 
2.1.6 Applications 
For biopharmaceutical applications, CZE-(TOF)MS analyses followed by multivariate 
statistics were used to compare, for example, EPO preparations [51]. The relative peak areas 
of the selected intact EPO isoforms were used as variables in principal component analysis 
(PCA) and hierarchical agglomerative clustering. Both strategies allowed EPO formulations 
to be differentiated according to manufacturer, production cell line, and batch number. The 
results of the PCA on the different EPO preparations are presented Figure 3. Small changes in 
antennarity, sialylation, and acetylation of isoforms were observed. This kind of strategy can 
be useful for quality control, optimization of the production or comparison of biosimilar with 
innovator. 
CZE-MS can also be used to accurately determine a precise mass after deconvolution of the 
charge distribution. However, elucidation of the composition of the intact glycoforms is 
impossible because different glycan combinations have the same mass, even with a very high 
resolution MS analyzer, such as Fourier transform-based MS [54]. This is why 
complementary approaches must also be implemented to characterize the glycoforms at the 
glycopeptide or glycan levels [38,39,48,54,56,63]. 
 
15 
 
Figure 3: Score plot for principal component 1 (PC 1) and principal component 2 (PC 2) of 
the principal component analysis on the different EPO preparations analyzed by CZE-MS. 
Reprinted with permission from [51]. 
 
Nevertheless, in some cases, the combination of MS spectra and CZE migration times allows 
the identification of major isoforms differing by only 1 Da (isoforms with one less sialic acid 
and two more fucose), as observed when analyzing AGP purified from human serum [39]. 
Figure 4 shows the electropherogram obtained with many peaks over 3 min, and the spectra 
and deconvoluted spectra of peaks 5 and 6. Differences in isoform composition can easily be 
observed. Indeed, AGP isoforms differing in one sialic acid have a molecular mass difference 
of 291 Da and are observed in two consecutive time windows: isoforms with a higher sialic 
acid content appear at lower migration times (Figure 4B). Within the same time window, 
observed masses correspond to the addition of HexHexNAc units (365 Da) or fucosylation 
(146 Da) (Figure 4C). A proof-of-concept study also demonstrated that the analysis of AGP in 
CZE-MS combined with statistical techniques allowed the identification of potential 
biomarkers of bladder cancer [40]. CZE-UV did not provide statistically different variables to 
differentiate healthy patients from cancer patients, but CZE-ESI-TOF showed to be a very 
appropriate technique to achieve this objective when the CZE migration times are taken into 
account with MS data.  
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Figure 4: Analysis by sheath liquid CE-MS of intact AGP (8 mg/ml) purified from human 
serum. (A) Base peak electropherogram. (B) spectra of peaks 5 and 6. (C) Deconvoluted 
spectra of peaks 5 and 6. ORM1 and ORM2 are the two main AGP isoforms, differing in 21 
amino acids. The ORM1 isoform presents 3 different variants, ORM1F1, ORM1F2, and 
ORM1S, while the ORM2 isoform presents the ORM2A variant. Reprinted with permission 
from [39]. 
 
17 
Recently, CZE-MS with a triple-quadripole (TQ) analyzer was used for the analysis of intact 
hCG and demonstrated its high potential for a fingerprinting approach, as it differentiated the 
isoform composition of 2 hCG-based drugs [55]. For identification, a high mass resolution is 
mandatory and, for isotopic resolution, the resolving power value must be higher than the 
molecular weight of the protein [50]. For example, proteins with a MW of 30 kDa require a 
MS with a resolving power of about 40,000 or more to be isotopically resolved. In this paper, 
the analysis illustrated that TOF MS is adequate for the isotopic resolution of intact proteins 
up to about 20 kDa (benchtop instrument) or 30 kDa (high resolution instrument).  
Other high resolution MS analyzers can be used, such as Orbitrap or Fourier transform ion 
cyclotron resonance (FT-ICR). However, the resolution of these mass spectrometers is 
inversely proportional to the acquisition time, which can be a dramatic issue when coupling to 
fast and high performance separation techniques like CE.  
MS allows also to perform in-source fragmentation as it was first carried out for the analysis 
of an intact glycoprotein by CZE-MS to obtain carbohydrate-specific reporter ions and to 
compare the internal ratio of Hex
+
/HexNAc
+
 of rhBMP-2 isoforms [44].  
With regard to quantification, unlike glycopeptides, for which it is not possible to assume that 
they have similar ESI ionization yields, this is possible for different intact glycoforms of a 
protein. Indeed, they often have the same maximum of the charge distribution after ESI 
ionization. In this case, the determination of the peak areas from the EIEs allows the 
comparison of their relative abundances, as it was already demonstrated by several authors 
[43,54,57]. The repeatability was studied using peak areas normalized by that of the most 
intense glycoform obtained during the analysis by CZE-ESI-(FT)MS of hCGα for which 60 
glycoforms were detected [54]. The average RSD (n=3) of the peak areas was less than 10%.  
Karger and coll. used a different method to do the relative quantitation of IFN-β isoforms 
[58]. They summed the EIE integrated signals of the 6 charge states with the highest ion 
intensities and divided it by the sum of the total signal for all proteoforms. The signal 
extraction window was centered (+65%/-35%) around the theoretical average masses for the 
given charge state within mass tolerance windows of 1.4, 1.3, 1.25, 1.15, 1.0 Da (z = +11 to 
+16, respectively). Considering a total relative abundance higher than 1.2% of the total peak 
intensity, a total of 55 isoforms were quantitated with less than 20% RSD (n=6). They used 
these quantitative data to try to correlate some protein modifications. Nevertheless, to take 
into account the potential differences in ionization efficiency of each glycoform, it is 
preferable to compare the results on a relative basis, such as from batch to batch or during a 
process. 
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As a perspective, some studies have recently described the implementation of separation in a 
microchip channel instead of a fused-silica capillary [42,70]. Ramsey and coll. carried out the 
separation of intact mAb variants (Infliximab and two other mAbs) in a glass etched channel 
of a chip (23-cm long, 10-µm depth, and 70-µm full width) having an integrated ESI emitter 
[70]. To avoid adsorption of the analyte and control EOF, a surface coating using chemical 
vapor deposition of an aminopropylsilane-based layer and a covalent modification of the 
resulting surface with polyethylene glycol were performed. This surface coating led to highly 
efficient separations, as illustrated in Figure 5, for Infliximab with a BGE composed of 10% 
2-propanol with 0.2% acetic acid (pH 3.2), which is fully MS compatible, unlike the BGE 
traditionally used for mAb charge variants based on triethylenetetramine or ε-aminocaproic 
acid. As shown in Figure 5, at least 4 mAb glycoforms can be identified per lysine variant, 
resulting in at least 12 mAb isoforms identified. Therefore, this miniaturized approach allows 
the determination of the mass of intact mAb variants and the assessment of charge 
heterogeneity and other glycoform information with a total analysis time of less than 4 min 
and a stable channel surface that does not require regular regeneration of the coating. This 
technique was then used to characterize other mAb and intact antibody drug conjugate 
variants [42]. 
 
Figure 5: (A) Schematic for CE-ESI-MS chip device with a 23 cm separation channel with an 
enlarged image of the asymmetric turn tapering. Red channels indicate an aminopropylsilane 
(APS) coating while black channels indicate an APS-polyethylene glycol coating. S, sample 
reservoir; B, BGE reservoir; SW, sample waste reservoir; EO, electroosmotic pump. (B) 
Analysis of intact Infliximab using the CE-ESI-MS chip device. (a) Identified lysine variants 
bands are labeled as 2-K, 1-K, and 0-K, which correspond to 2-Lysine, 1-Lysine, and 0-
Lysine variants, respectively. (b) Deconvoluted mass spectra for each lysine variant with 
glycosylation structures above the mass of each peak. Reprinted with permission from [70]. 
A B
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2.2 Capillary isoelectric focusing 
The on-line hyphenation of CIEF with MS is not straightforward due to the non-volatile 
ampholytes, acids, and bases needed to get separations with high resolution. Several strategies 
can overcome this problem, such as the use of low ampholyte concentration, an interim 
separation by chromatography, the use of a dialysis interface to remove the interfering 
substances or the partial ampholyte filling technique, as reviewed by Hühner et al. [71]. As an 
example, CIEF was applied to the analysis of bovine serum apotransferrin glycoforms to 
separate the di-, tri-, and tetrasiallotransferrins [72].  
Very recently, CIEF has been directly coupled to MS with a stainless-steel flow-through 
microvial ESI interface [73]. A very small amount of an intact mAb (30 ng of Infliximab) was 
analyzed and 15 intact molecular weight values originating from glycosylation heterogeneity 
and charge variation were observed, while 13 were identified thanks to the use of an Orbitrap 
analyzer. A recent paper dealing with the coupling of imaged CIEF with MS using a nanoliter 
valve for the analysis of intact mAb variants demonstrated once again the high potential of 
CIEF-MS for the analysis of protein glycoforms [74].  
It is also worthwhile to notice that Shimura reviewed the advances of CIEF implemented in 
microchips for the separation of proteins at the intact level [75]. However, separation 
resolution and automation still need to be improved before using this technique for the 
analysis of protein glycosylation. 
 
3. Liquid chromatography 
LC is also a powerful method for the separation of intact proteins due to its high-resolving 
power, good reproducibility, and compatibility with MS [76]. In recent years, significant 
developments have occurred to improve its potential for the protein analysis, such as the 
development of bio-inert systems to prevent the risk of adsorption. New stationary phases 
adapted for the analysis of intact proteins, such as sub-2-microns particles and superficially 
porous particles [77] and with large pore sizes (> 200 Å), also appeared, leading to higher 
efficiencies in shorter analysis times. The performance of these new stationary phases packed 
in columns with conventional dimensions (2.1 x 150 mm), especially for the separation of 
therapeutic mAbs, was recently reviewed [78,79]. Columns with nano (25 µm < i.d. < 100 
µm) and micro (100 µm < i.d. < 1 mm) formats are also interesting because they lead to high 
sensitivity, while requiring less sample and mobile phase, and can be directly hyphenated with 
nano-ESI MS [80]. 
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A wide variety of separation modes can be used for protein analysis, including hydrophilic 
interaction liquid chromatography (HILIC), reversed-phase liquid chromatography (RPLC), 
hydrophobic interaction chromatography (HIC), ion-exchange chromatography, and size 
exclusion chromatography [76,81]. The consideration of the MS compatibility criterion 
explains why RPLC and HILIC have been the most widely used in this field.  
 
3.1 Reversed-phase liquid chromatography 
RPLC is widely used to separate glycopeptides obtained after enzymatic digestion of the 
protein [82,83], but its application to the analysis of intact proteins is more complex due to 
their adsorption, pore exclusion, and low diffusion coefficient [84]. However, some strategies 
were proposed to overcome these problems by using of (i) silica-based stationary phases with 
restricted access to residual silanol (e.g. end-capped, hybrid silica, high density bonding, or 
embedded polar group stationary phase), (ii) elevated temperature, (iii) particles with large 
pore sizes (> 200Å), and (vi) addition of TFA or FA in the mobile phase to reduce adsorption, 
as already mentioned in reviews devoted to biopharmaceutical characterization [33,85].  
Focusing on studies on the characterization of protein glycosylation by RPLC, a review of the 
literature is presented in Table 2. It deals mainly with studies on mAbs, but also on EPO, Tf 
or hCG. The most commonly used stationary phase is a C8-bonded silica. It is interesting to 
note that a Tf-exendin fusion protein was used to study the role of sugars in interactions 
between the protein backbone and the hydrophobic ligand on the LC stationary phase [102]. 
Indeed, this protein has the N-linked sited removed, leading to a less complex glycoprotein 
containing only linear Man residues at the Ser and Thr residues. A C18-bonded silica was 
selected and it was observed that retention time increases as the number of Man decreases.  
A gradient composed of a mixture of ACN and water is generally applied sometimes with 
some n-propanol which can help to mask residual silanol groups. A small content (0.02-0.1%) 
of an acid is always added in the mobile phase either to favor glycoform separation (TFA) or 
to enhance the MS signal (FA). Since FA does not improve selectivity and TFA reduces the 
MS signal, they are sometimes both introduced in the mobile phase, but keeping TFA content 
as low as possible (0.02%). In Table 2, it also appears that a high column temperature is 
always chosen, between 50 and 80°C. Indeed, an increase in temperature has a significant 
positive impact on glycoform separation, as observed for example with a recombinant hCG-
based drug analysis giving more than 10 chromatographic peaks at 65°C (Figure 6) instead of 
6 at 35°C [88]. It is worthwhile to notice that the large peak between 33 and 35 min 
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corresponds to the co-elution of hCG isoforms, that are very numerous because hCG has 8 
glycosylation sites plus other potential PTMs. 
 
 
Figure 6: TIC chromatogram obtained by RPLC-MS analysis of a recombinant hCG-based 
drug. Reprinted with permission from [88]. 
 
One of the first papers dealing with the RPLC-MS analysis of an intact glycoprotein also 
concerns hCG [87]. It combined the results of glycan identification after tryptic digestion with 
molecular mass measurements of intact hCG after its separation on a monolithic capillary 
column and detection in a quadrupole IT analyzer tuned to detect low charge states of 
glycoforms. The annotation of glycoforms observed in deconvoluted mass spectra was 
accomplished by an algorithm comparing the measured molecular masses and a database 
derived from the known glycan composition and possible modifications of the protein 
backbone. This method allowed the annotation of 7 glycoforms of hCGα in Pregnyl, a hCG-
based drug, with a minimal sample preparation (only ultra-filtration through a cutoff 5000 
membrane) by LC analysis in less than 15 min.  
Of course, this approach was also quickly evaluated for the analysis of mAbs, which are 
proteins with significantly higher molecular masses [90-92]. Although their wide isotopic 
distribution makes it difficult to resolve their glycoforms completely, it provides an overall 
view of their heterogeneity. This allows a fast comparison of mAb batches, as illustrated 
Figure 7 (top). Today, the use of UHPLC hyphenated with a qTOF analyzer allows a better 
accuracy and precision for identification with a duration of less than 10 min per analysis [94].  
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Figure 7: (Top) Deconvoluted spectra of two different lots (a and b) of the same recombinant 
mAb analyzed by RPLC-MS at the intact level. The peak labels refer to the various 
glycoforms identified base on the deconvoluted mass. Reprinted with permission from [92].  
(Bottom) Analysis by nanoRPLC-chip-MS of two different mAbs, Trastuzumab and 
Bevacizumab. (A) TIC with elution of Trastuzumab highlighted in shaded grey. (B) Multiple 
charged ion distribution of Trastuzumab. Reconstructed mass spectrum with annotation of the 
glycoforms of (C) Trastuzumab and (D) Bevacizumab. Reprinted with permission from [95]. 
 
The hyphenation of LC with an analyzer with an even higher mass resolution such as an 
Orbitrap is also of interest. This was used for the characterization of mAb variants in 
fermentation broth, as the dilute-and-shoot method developed by Huber and coll. [96]. With a 
short RPLC-(qOrbitrap)MS analysis achieved in 15 min, N-glycosylation and truncation 
A
DB
C
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variants of the expressed mAb were identified at the intact protein level. The robustness and 
repeatability of the method were assessed with regard to retention time, peak area, and mass 
resolution. The precision of the molecular mass determination, expressed as a 95% confidence 
interval, ranged from ± 0.16 to ± 2.89 Da for 6 replicates. After 965 injections of the mAb 
reference material or fermentation samples, retention times and peak widths at half-height 
differed by only 4.8 and 0.06 s, respectively. A relative quantification of mAb glycoforms 
was then performed with extracted ion current chromatograms based on the theoretical mass 
of the respective species. The average fractional abundance of each glycoform was calculated 
from the measured peak areas. However, the absence of a validated mAb standard hinders the 
direct evaluation of the trueness of glycoform quantification by MS. In addition, the ability of 
LC-(Orbitrap)MS analysis of an intact protein to characterize its glycosylation may be limited 
when some glycoforms are in low abundance and/or when many glycosylation sites and other 
PTMs are present. A recent study investigated the effect of various parameters of an Orbitrap 
hyphenated with LC, including source temperature, microscan type and quantity, mass 
resolution, and automatic gain control on spectral quality [97]. Several human proteins of 
diagnostic or of therapeutic interest were selected as model proteins (C-reactive protein, 
vitamin D-binding protein, Tf, and IgG). For example, the optimized source temperature was 
found to be specific to each protein. A methodological framework was established to ensure a 
robust glycoform identification, before their quantification. 
One of the current LC trends is miniaturization. This is also the case for glycosylation 
characterization. Harazono et al. compared the glycoform profiles of the innovator and a 
biosimilar of EPO by nanoRPLC-MS [86]. Due to the high micro-heterogeneity of glycans, 
the chromatograms had a massif with a ten of summits and the mass spectrum was obtained 
either over the entire elution period (18.7-20 min) or over short elution periods (18.7-18.9 
min, 18.9-19 min, …) before deconvolution. The first approach is fast and led to the detection 
of major glycoforms, while the second takes more time but shows minor glycoforms. The first 
approach was used to compare EPO innovators and biosimilars, as the RSDs of the relative 
peak intensities, assumed to correspond to those measured on MS spectra, were close to or 
less than 10% for major-to-moderate glycoforms (n=4). RPLC-MS allowed rapid glycoform 
profiling and assessment of the similarity of glycoprotein-based pharmaceuticals. The second 
approach demonstrated that glycoforms containing less sialic acids eluted much earlier, and 
those containing larger glycans eluted slightly earlier.  
Some authors also proposed to carry out separations on chips [95,100,101]. However, a 
dramatic decrease in the column dimensions limits the amount of sample that can be injected. 
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Therefore, the use of a trapping column may be a good alternative to increase the injected 
sample volumes and to concentrate isoforms before their separation, although care must be 
taken to avoid the potential loss of the most hydrophilic glycoforms during trapping on the 
reduced size precolumn [95]. This method was used to compare the glycosylation profiles of 
different monoclonal IgG-based biopharmaceuticals at the intact level, as illustrated for 
Trastuzumab and Bevacizumab (Figure 7 bottom). Its robustness was assessed with RSD 
values of 2.2% and 3.7% in terms of relative abundance for intra- and inter-assay variability, 
respectively. It also allowed the evaluation of batch-to-batch variations in the glycoform 
heterogeneity. The same group also applied this method for the glycoprofiling of Tf in plasma 
samples of controls, patients with known defects, and patients with secondary or unsolved 
cause of abnormal glycosylation [100]. After an immunoextraction step, the analysis led to 
distinct glycosylation profiles, which facilitated the identification of the specific congenital 
disorders of glycosylation subtype.  
With regard to diagnosis, another example is the RPLC-MS analysis of 6 multifucosylated 
glycoforms of the basic proline-rich protein IB-8a CON1
+
 (so called according to its 
interaction with concanavalin A) in human saliva [89]. The sample pretreatment consisted of a 
simple dilution (1/1) with an acidic solution (0.2% TFA) and a centrifugation step for 10 min. 
A similar study was performed by the same group to characterize the glycoforms of a basic 
salivary proline-rich protein 3M [99]. 
 
3.2 Hydrophilic interaction liquid chromatography 
There is an ongoing effort nowadays to evaluate the potential of HILIC for the 
characterization of intact glycoproteins [103-107]. Indeed, HILIC is already widely used 
routinely for the analysis of released glycans and glycopeptides [108]. With this mode, 
retention is mainly based on partitioning of the analytes between a water-enriched layer 
formed at the surface of a polar stationary phase and the hydro-organic mobile phase, and 
interactions with the stationary phase (hydrogen bonds, ionic and dipole-dipole interactions) 
[103,109]. The high organic solvent content of the mobile phase improves its volatility, which 
favors the hyphenation with MS, leading to an improvement in sensitivity for a large variety 
of compounds [110]. Periat et al. were the first to demonstrate the potential of HILIC as an 
orthogonal approach to reversed-phase LC for the characterization of mAb glycoforms at the 
protein level [111]. For the characterization of protein glycosylation by HILIC analysis 
hyphenated to MS, an overview of the literature is presented in Table 3. As far as we know, 
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only a few papers have been published, dealing with RNase B [114], neo-glycoprotein such as 
Ag85B and TB10.4 [112], or IFN-β and EPO [113]. 
Several HILIC columns were tested to separate the intact isoforms of these glycoproteins, but 
amide-based silica seems to be the gold standard (see Table 3). Most amide-based stationary 
phases have pore sizes between 80 and 150 Å, which can exclude the largest glycoforms from 
the pores. To the best of our knowledge, only the AdvanceBio Glycan Mapping
®
 (Agilent 
Technologies) and Glycoprotein BEH Amide
®
 (Waters) columns have a pore size of 300 Å. 
Zhang et al. reported the use of an innovative, laboratory-made stationary phase based on 
non-porous silica particles bonded with linear polyacrylamide chains for the separation of 5 
intact high-mannose N-glycoforms of RNase B [114]. The brush layer was designed to be 
closely spaced to sterically exclude proteins, thus avoiding protein-silanol interactions, while 
glycans can penetrate it. With regard to the retention mechanism, the protein backbone would 
be adsorbed just on the surface of the polyacrylamide and the glycan moieties would 
contribute as a function of their partitioning in the hydrophilic layer. RNaseB was selected as 
a model protein, with N-glycans varying from 5 to 9 Man groups. Its 5 glycoforms were 
baseline resolved and even more peaks were resolved using 700 nm particles compared to 
those of 1.4 µm, corresponding to glycoform isomers, but only when HILIC was coupled with 
UV, which allows the use of a high percentage of TFA (0.1%) in the mobile phase. The 
performances were better than those obtained with two commercial HILIC columns (BEH 
amide column, 2.1 x 30 mm, 1.7 µm, and a TSKgel amide-80 clumb, 2 x 50 mm, 3 µm), with 
a separation temperature of only 30°C compared to 60°C for the other two. In HILIC-MS, the 
amount of TFA was reduced to 0.02% until acceptable MS spectra were obtained and 0.5% of 
FA was included. In this case, the resolution was divided by a factor of 2.  
Typically, the mobile phase consists of a high percentage of ACN plus water acidified with 
TFA, acting as an ion-pairing agent and generating some solvating effect that both impact 
selectivity, retention, resolution, and peak shape. Indeed, Tengattini et al. demonstrated its 
large influence on the separation resolution of intact glycoforms of RNase B [112]. Different 
TFA contents were tested and compared to the use of other acidic additives such as FA or 
perchloric acid. From these experiments, it appears that at least 0.05% of TFA must be used to 
achieve a satisfactory separation of glycoforms. 
TFA is a corrosive agent that can cause irreversible damage to the MS detector and also leads 
to a high ion suppression effect. Zhang et al. reduced its concentration by using 0.05% instead 
of 0.1% (used in UV conditions) and adding 0.5% of FA. Nevertheless, a dramatic loss of 
resolution was observed for the separation of ribonuclease B glycoforms [114]. In another 
26 
study, Dominguez-Vega et al. reported about the interest of in-source collision-induced 
dissociation, which minimizes the protein-signal suppression induced by TFA [113]. 
Therefore, TFA in mobile phase is essential in HILIC to obtain an efficient separation of 
intact isoforms, but it results in a dramatic decrease in signal, highlighting the current 
limitations of HILIC-MS for the analysis of protein glycosylation. 
Another main challenge in HILIC for the analysis of intact glycoproteins is to determine 
injection conditions that will not lead to significant deformation of chromatographic peaks. 
Indeed, the dissolution of glycoproteins in high ACN content (e.g. 70-90%) close to the 
mobile phase composition cannot be achieved because they precipitate [35]. Nevertheless, 
some studies reported the use of relatively high-percentages (i.e. 90-50%) of organic solvent 
[112,114], but there is a risk of having only a partial dissolution of the protein isoforms. 
Therefore, another approach consists in dissolving the protein in water and to inject a low 
volume to prevent peak shape deformation induced by the high percentage of water [113]. For 
an injection volume of 1 μl, the sample-to-column volume ratio is 0.2% for a standard LC 
column (150 x 2.1 mm, approx. 415 µl with a porosity value of 0.8), which is acceptable for 
the amount of water introduced on the HILIC column.  
With regard to column temperature, Periat et al. demonstrated that temperature does not have 
as much effect in HILIC as in RPLC [111]. In Table 3, it appears that values between 30 and 
60°C are commonly used for the separation of glycoforms.  
For applications, HILIC coupled to MS showed its potential for the characterization of intact 
neo-glycoproteins obtained after a glycosylation procedure from ribonuclease A, and 2 
antigenic proteins, namely TB10.4 and Ag85B [112]. Additional MS/MS experiments 
confirmed the localization of the N-glycosylation site. In this case, selectivity depended 
mainly on the size and number of glycans attached to the protein, but it should be noted that 
these semi-synthetic glycoproteins contain glycans composed only of Man, which highly 
reduces the number of isoforms and thus the complexity of HILIC separation.  
A HILIC-MS method was also applied to the profiling of IFN-β and EPO [113]. A 
chromatogram of IFN-β is presented in Figure 8A. Even if an incomplete separation was 
obtained, various glycoforms were detected, differing by the number of Fuc, hexose, and 
sialic acid. Figure 8B shows that the neutral glycan units contribute significantly to glycoform 
separation, whereas terminal sialic acids only slightly affect the HILIC retention. Other PTMs 
such as oxidation, succinimide intermediates, and loss of N-terminal methionine were also 
observed (Figure 8C). The same analytical method was applied to the analysis of EPO and 
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allowed to elucidate the composition of 12 and 51 glycoforms of IFN-β and EPO, 
respectively. 
 
 
Figure 8: HILIC-MS of IFN-β. (A) Base-peak chromatogram; (B) Extracted-ion 
chromatograms of the detected glycoforms with tentative glycan assignment; (C) Extracted-
ion chromatograms of the most abundant glycoforms. Reprinted with permission from [113]. 
 
3.3 Other LC modes 
Ion-exchange chromatography provides a separation mode orthogonal to RPLC and is very 
useful for the characterization of charge variants, and thus of the glycoforms. Nevertheless, it 
requires mobile phases with high concentrations of non-volatile salts non-easily compatible 
with MS. However, a strategy based on on-line two-dimensional LC-MS can be used, 
coupling IEX with RPLC in order to separate glycoforms according to their charge in the first 
dimension and desalt the medium with a small RPLC trapping column in the second. This 
approach was used, for example, to characterize mAb glycoforms [115]. Up to 6 fractions of 
interest from ion exchange separation were analyzed by trapping and desalting the fractions 
onto a series of reversed phase trap cartridges with subsequent on-line analysis by MS. The 
analysis of the acidic peaks of a mAb revealed the presence of glycans with varied degrees of 
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sialylation. It is important to note that if, in this study, the sole objective of the RPLC sorbent 
was a rapid desalting of fractions prior to their MS analysis, a column could be incorporated 
for additional separation prior to MS detection. The optimization of MS-compatible mobile 
phases for IEX separation of mAbs was recently investigated and seems to be very promising 
in the future for glycoform separation [116]. 
HIC is a popular non-denaturing separation mode to analyze proteins, but most often it uses 
mobile phases that are not compatible with MS. Recently, Ge and coll. reported the first on-
line coupling of HIC to MS using more hydrophobic columns and ammonium acetate with an 
organic solvent as mobile phase for the analysis of proteins [117]. This new methodology was 
then investigated with mAbs and allowed the determination of relative hydrophobicity with 
HIC, and of intact masses and glycosylation profiles with MS [118]. However, the addition of 
solvent in the organic phase can denature the protein and therefore one of the key advantages 
of the HILIC mode could be lost. The growing interest in this approach should expand the 
toolbox for characterizing glycoproteins.  
Secondly, it is generally considered that size exclusion chromatography (SEC) cannot provide 
any information on glycosylation, as it has the lowest efficiency and resolution of all 
chromatographic modes. Nevertheless, SEC using a mobile phase based on ACN with 0.1% 
FA and 0.1% TFA and hyphenated with a qTOF MS analyzer has recently been successfully 
applied to the analysis of intact Trastuzumab and a detailed glycosylation pattern was 
obtained [119]. This can allow the analysis of proteins in their native state, which is 
particularly important to study molecules maintained by non-covalent interactions. 
Affinity chromatography can also be an effective technique to separate glycoforms, based on 
their reversible adsorption on a stationary phase with specific ligands immobilized on its 
surface. Affinity chromatography involving protein A-based sorbent is useful to recover 
antibodies from complex solutions such as culture supernatants. This technique was thus on-
line hyphenated with RPLC-MS via a desalting pre-column to evaluate the glycan 
heterogeneity of different mAbs diluted in water, serum-free medium, and Chinese hamster 
ovary cell culture supernatant [120]. All three types of samples gave similar glycoform 
patterns, suggesting that this system avoids interferences from media components or host cell 
proteins. The analysis of Rituximab samples diluted with serum-free medium were repeated 6 
times per day for 3 days. The height of the 4 major peaks in the deconvoluted MS spectra 
were measured and the RSDs (3 days) of each relative peak height against total peak height 
ranged from 1.0 to 5.3%. Two other mAbs (Trastuzumab and Palivizumab) were also 
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analyzed with this approach and gave significantly different patterns of the main glycoforms, 
with different galactosylation and fucosylation levels.  
A similar approach was used to detect novel proteoforms of apolipoprotein A-I (ApoA-I) in 
serum [121]. An immunoaffinity column was home-made and consisted in immobilized anti-
ApoA-I antibodies on POROS-aldehyde sorbent. The immunoaffinity column was coupled to 
a trapping-separation C4 monolithic column (1 x 50 mm) hyphenated to a qOrbitrap. It 
allowed the detection for the first time of a glycosylated form of ApoA-I in human in vivo 
samples. More recently, a heart-cutting 2D-LC set up combining protein A with RPLC-MS 
was used to select mAb producing clones based on glycosylation [122]. Once again, the 
RPLC column was mainly used for desalting. These multi-dimensional approaches, coupling 
orthogonal separation modes and favoring the coupling with MS, should be more and more 
developed for the characterization of glycosylation as they dramatically enhance the 
separation power, especially when they are combined with very high resolution MS.  
 
4. Conclusion 
In this review, we focused on the potential of high performance separation techniques 
hyphenated to MS for the characterization of the protein glycosylation at the intact level. 
CZE-MS has been used extensively and successfully but is still considered a complex 
technique, requiring a specific expertise. The development of a more user-friendly interface 
could certainly facilitate its use in the near future. The use of HPLC in thus domain is more 
recent and continues to grow. Nowadays, only two modes, RP and HILIC, can be easily 
hyphenated with MS. The development of new stationary phases with an adapted pore size 
should support this growth and there is no doubt that new proteins and new application fields 
should be targeted in the future. It can also be expected that, in a few years, additional CE and 
LC modes, such as CIEF for example, will be routinely used for the glycosylation 
characterization of proteins when their hyphenation with MS will be easier. The future will 
also be based on the development of multidimensional approaches. 
For both CZE and LC hyphenated with MS, two kinds of applications can be discussed 
depending on the resolution of the mass analyzer. Low mass resolution spectrometers are 
sufficient for a fingerprinting approach based on glycoprofiling. However, for identification 
purposes, the high mass resolution analyzers are required. Therefore, the increased 
availability of high resolution and high accuracy MS analyzers will support the development 
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of the analysis of glycoproteins at the intact level. For proteins of small size and/or low 
glycosylation site number, it may be sufficient to characterize their glycoforms.   
 
References 
 
[1] A. Shajahan, C. Heiss, M. Ishihara, P. Azadi, Glycomic and glycoproteomic analysis of 
glycoproteins—a tutorial, Anal. Bioanal. Chem. 409 (2017) 4483–4505. doi:10.1007/s00216-017-
0406-7. 
[2] Y. Mechref, D.C. Muddiman, Recent advances in glycomics, glycoproteomics and allied topics, 
Anal. Bioanal. Chem. 409 (2017) 355–357. doi:10.1007/s00216-016-0093-9. 
[3] J. Guibourdenche, L. Burc, J.. Frendo, G. Flament, A. Kacprzak, I. Bazot, P. Jeanne, D. Porquet, F. 
Muller, Physiopathologie de l’hormone chorionique gonadotrope humaine (hCG) dans la trisomie 21 
fœtale, Immuno-Anal. Biol. Spéc. 17 (2002) 2–10. doi:10.1016/S0923-2532(02)01159-6. 
[6] M.C. Patterson, Metabolic mimics: the disorders of N-linked glycosylation, Semin. Pediatr. 
Neurol. 12 (2005) 144–151. 
[7] R. Goulabchand, T. Vincent, F. Batteux, J. Eliaou, P. Guilpain, Impact of autoantibody 
glycosylation in autoimmune diseases, Autoimmun. Rev. 13 (2014) 742–750. 
doi:10.1016/j.autrev.2014.02.005. 
[8] P.J. Delves, The Role of Glycosylation in Autoimmune Disease, Autoimmunity. 27 (1998) 239–
253. doi:10.3109/08916939808993836. 
[9] M.K. Sethi, J. Zaia, Extracellular matrix proteomics in schizophrenia and Alzheimer’s disease, 
Anal. Bioanal. Chem. 409 (2017) 379–394. doi:10.1007/s00216-016-9900-6. 
[10] M.J. Kailemia, D. Park, C.B. Lebrilla, Glycans and glycoproteins as specific biomarkers for 
cancer, Anal. Bioanal. Chem. 409 (2017) 395–410. doi:10.1007/s00216-016-9880-6. 
[11] B. Adamczyk, T. Tharmalingam, P.M. Rudd, Glycans as cancer biomarkers, Biochim. Biophys. 
Acta BBA - Gen. Subj. 1820 (2012) 1347–1353. doi:10.1016/j.bbagen.2011.12.001. 
[12] M. Polanski, N.L. Anderson, A List of Candidate Cancer Biomarkers for Targeted Proteomics, 
Biomark. Insights. 1 (2006) 117727190600100. doi:10.1177/117727190600100001. 
[13] R. Barone, L. Sturiale, A. Palmigiano, M. Zappia, D. Garozzo, Glycomics of pediatric and 
adulthood diseases of the central nervous system, J. Proteomics. 75 (2012) 5123–5139. 
doi:10.1016/j.jprot.2012.07.007. 
[14] S.E. Sparks, Inherited Disorders of Glycosylation, in: John Wiley & Sons, Ltd (Ed.), Encycl. Life 
Sci., John Wiley & Sons, Ltd, Chichester, UK, 2007. doi:10.1002/9780470015902.a0020230. 
[4] A. Planinc, J. Bones, B. Dejaegher, P. Van Antwerpen, C. Delporte, Glycan characterization of 
biopharmaceuticals: Updates and perspectives, Anal. Chim. Acta. 921 (2016) 13–27. 
doi:10.1016/j.aca.2016.03.049. 
[5] S. Amon, A.D. Zamfir, A. Rizzi, Glycosylation analysis of glycoproteins and proteoglycans using 
capillary electrophoresis-mass spectrometry strategies, Electrophoresis 29 (2008) 2485-2507. 
doi:10.1002/elps.200800105. 
 [15] A. Helenius, Intracellular Functions of N-Linked Glycans, Science. 291 (2001) 2364–2369. 
doi:10.1126/science.291.5512.2364. 
[16] A. Varki, ed., Essentials of glycobiology, 2nd ed, Cold Spring Harbor Laboratory Press, Cold 
Spring Harbor, N.Y, 2009. 
31 
[17] S. Fekete, D. Guillarme, P. Sandra, K. Sandra, Chromatographic, Electrophoretic, and Mass 
Spectrometric Methods for the Analytical Characterization of Protein Biopharmaceuticals, Anal. 
Chem. 88 (2016) 480–507. doi:10.1021/acs.analchem.5b04561. 
[18] V. Kolli, K.N. Schumacher, E.D. Dodds, Engaging challenges in glycoproteomics: recent 
advances in MS-based glycopeptide analysis, Bioanalysis. 7 (2015) 113–131. doi:10.4155/bio.14.272. 
[19] W.R.J. Alley, B.F. Mann, M.V. Novotny, High sensitivity analytical approaches for the structural 
characterization of glycoproteins, Chem. Rev. 113 (2013) 2668-2732. doi:10.1021/cr3003714. 
[20] R. Zhu, L. Zacharias, K.M. Wooding, W. Peng, Y. Mechref, Glycoprotein enrichment analytical 
techniques: advantages and disadvantages, in Methods in Enzymology, ed. Elsevier, 585 (2017) 397-
429. doi:10.1016/bs.mie.2016.11.009. 
[21] A. Beck, E. Wagner-Rousset, D. Ayoub, A. Van Dorsselaer, S. Sanglier-Cianferani, 
Characterization of therapeutic antibodies and related products, Anal. Chem. 85 (2013) 715-736. 
doi:10.1021/ac3032355. 
[22] E. Largy, F. Cantais, G. Van Vyncht, A. Beck, A. Delobel, Orthogonal liquid chromatography-
mass spectrometry methods for the comprehensive characterization of therapeutic glycoproteins, from 
released glycans to intact protein level, J. Chromatogr. A 1498 (2017) 128-146. 
doi:10.1016/j.chroma.2017.02.072. 
[23] T. Tharmalingam, B. Adamczyk, M.A. Doherty, L. Royle, P.M. Rudd, Strategies for the 
profiling, characterisation and detailed structural analysis of N-linked oligosaccharides, Glycoconj. J. 
30 (2013) 137–146. doi:10.1007/s10719-012-9443-9. 
[24] M. Pabst, F. Altmann, Glycan analysis by modern instrumental methods, PROTEOMICS. 11 
(2011) 631–643. doi:10.1002/pmic.201000517. 
[25] A. Palmigiano, A. Messina, L. Sturiale, D. Garozzo, Advanced LC-MS Methods for N-Glycan 
Characterization, in: Compr. Anal. Chem., Elsevier, 2018: pp. 147–172. 
doi:10.1016/bs.coac.2017.06.009. 
[26] T. Merry, S. Astrautsova, Chemical and Enzymatic Release of Glycans from Glycoproteins, in: 
Capill. Electrophor. Carbohydr., Humana Press, New Jersey, 2003: pp. 27–40. doi:10.1385/1-59259-
294-5:27. 
[27] Y. Zhang, Y. Peng, L. Yang, H. Lu, Advances in sample preparation strategies for MS-based 
qualitative and quantitative N-glycomics, TrAC Trends Anal. Chem. 99 (2018) 34–46. 
doi:10.1016/j.trac.2017.11.013. 
[28] R. Haselberg, G.J. de Jong, G.W. Somsen, Capillary electrophoresis-mass spectrometry for the 
analysis of intact proteins 2007-2010, Electrophoresis 32 (2011) 66–82. doi:10.1002/elps.201000364. 
[29] V. Dotz, R. Haselberg, A. Shubhakar, R.P. Kozak, D. Falck, Y. Rombouts, D. Reusch, G.W. 
Somsen, D.L. Fernandes, M. Wuhrer, Mass spectrometry for glycosylation analysis of 
biopharmaceuticals, TrAC Trends Anal. Chem. 73 (2015) 1–9. doi:10.1016/j.trac.2015.04.024. 
[30] H. Geyer, R. Geyer, Strategies for analysis of glycoprotein glycosylation, Biochim. Biophys. Acta 
BBA - Proteins Proteomics. 1764 (2006) 1853–1869. doi:10.1016/j.bbapap.2006.10.007. 
[31] R. Haselberg, G.J. de Jong, G.W. Somsen, CE-MS for the analysis of intact proteins 2010-2012: 
CE and CEC, Electrophoresis 34 (2013) 99–112. doi:10.1002/elps.201200439. 
[32] R. Haselberg, G.J. de Jong, G.W. Somsen, Capillary electrophoresis–mass spectrometry for the 
analysis of intact proteins, J. Chromatogr. A. 1159 (2007) 81–109. doi:10.1016/j.chroma.2007.05.048. 
[33] A. Staub, D. Guillarme, J. Schappler, J.-L. Veuthey, S. Rudaz, Intact protein analysis in the 
biopharmaceutical field, J. Pharm. Biomed. Anal. 55 (2011) 810–822. doi:10.1016/j.jpba.2011.01.031. 
32 
[34] A.L. Capriotti, C. Cavaliere, P. Foglia, R. Samperi, A. Laganà, Intact protein separation by 
chromatographic and/or electrophoretic techniques for top-down proteomics, J. Chromatogr. A. 1218 
(2011) 8760–8776. doi:10.1016/j.chroma.2011.05.094. 
[35] A. Astefanei, I. Dapic, M. Camenzuli, Different Stationary Phase Selectivities and Morphologies 
for Intact Protein Separations, Chromatographia. 80 (2017) 665–687. doi:10.1007/s10337-016-3168-z. 
[36] M. Girard, A. Puerta, J.C. Diez-Masa, M. de Frutos, High resolution separation methods for the 
determination of intact human erythropoiesis stimulating agents. A review, Anal. Chim. Acta 713 
(2012) 7-22. doi:10.1016/j.aca.2001.11.041. 
[37] A. Staub, J. Schappler, S. Rudaz, J.-L. Veuthey, CE-TOF/MS: Fundamental concepts, 
instrumental considerations and applications, Electrophoresis 30 (2009) 1610–1623. 
doi:10.1002/elps.200800782. 
[38] E. Balaguer, C. Neusüβ, Glycoprotein Characterization Combining Intact Protein and Glycan 
Analysis by Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry, Anal. Chem. 78 
(2006) 5384–5393. doi:10.1021/ac060376g. 
[39] S. Ongay, C. Neusüβ, Isoform differentiation of intact AGP from human serum by capillary 
electrophoresis–mass spectrometry, Anal. Bioanal. Chem. 398 (2010) 845–855. doi:10.1007/s00216-
010-3948-5. 
[40] S. Ongay, P.J. Martín-Álvarez, C. Neusüß, M. de Frutos, Statistical evaluation of CZE-UV and 
CZE-ESI-MS data of intact α-1-acid glycoprotein isoforms for their use as potential biomarkers in 
bladder cancer, Electrophoresis 31 (2010) 3314–3325. doi:10.1002/elps.201000244. 
[41] S. Ongay, C. Neusüβ, S. Vaas, J.C. Diez-Masa, Evaluation of the effect of the 
immunopurification-based procedures on the CZE-UV and CZE-ESI-TOF-MS determination of 
isoforms of intact α-1-acid glycoprotein from human serum, Electrophoresis 31 (2010) 1796-1804. 
doi:10.1002/elps.200900680. 
 [42] E.A. Redman, J.S. Mellors, J.A. Starkey, J.M. Ramsey, Characterization of intact antibody drug 
conjugate variants using microfluidic capillary electrophoresis-mass spectrometry, Anal. Chem. 88 
(2016) 2220-2226. doi:10.1021/acs.analchem.5b03866. 
[43] U.M. Demelbauer, A. Plematl, L. Kremser, G. Allmaier, D. Josic, A. Rizzi, Characterization of 
glyco isoforms in plasmaderived human antithrombin by on-line capillary zone electrophoresis-
electrospray ionization-quadrupole ion trap-mass spectrometry of the intact glycoproteins, 
Electrophoresis 25 (2004) 2026–2032. doi:10.1002/elps.200305936. 
 [44] B. Yeung, T.J. Porter, J.E. Vath, Direct Isoform Analysis of High-Mannose-Containing 
Glycoproteins by On-Line Capillary Electrophoresis Electrospray Mass Spectrometry, Anal. Chem. 69 
(1997) 2510–2516. doi:10.1021/ac9611172. 
[45] C. Neusüß, U. Demelbauer, M. Pelzing, Glycoform characterization of intact erythropoietin by 
capillary electrophoresis-electrospray-time of flight-mass spectrometry, Electrophoresis 26 (2005) 
1442–1450. doi:10.1002/elps.200410269. 
[46] B. Yu, H. Cong, H. Liu, Y. Li, F. Liu, Ionene-dynamically coated capillary for analysis of urinary 
and recombinant human erythropoietin by capillary electrophoresis and online electrospray ionization 
mass spectrometry, J. Sep. Sci. 28 (2005) 2390-2400. doi:10.1002/jssc.200500156. 
[47] E. Balaguer, C. Neusüß, Intact Glycoform Characterization of Erythropoietin-α and 
Erythropoietin-β by CZE-ESI-TOF-MS, Chromatographia. 64 (2006) 351–357. doi:10.1365/s10337-
006-0787-9. 
[48] E. Balaguer, U. Demelbauer, M. Pelzing, V. Sanz-Nebot, J. Barbosa, C. Neusüß, Glycoform 
characterization of erythropoietin combining glycan and intact protein analysis by capillary 
33 
electrophoresis-electrospray -time-of-flight mass spectrometry, Electrophoresis 27 (2006) 2638–2650. 
doi:10.1002/elps.200600075. 
[49] E. Giménez, F. Benavente, J. Barbosa, V. Sanz-Nebot, Analysis of intact erythropoietin and novel 
erythropoiesis-stimulating protein by capillary electrophoresis-electrospray-ion trap mass 
spectrometry, Electrophoresis 29 (2008) 2161–2170. doi:10.1002/elps.200700788. 
[50] A. Taichrib, M. Pelzing, C. Pellegrino, M. Rossi, C. Neusüß, High resolution TOF MS coupled to 
CE for the analysis of isotopically resolved intact proteins, J. Proteomics. 74 (2011) 958–966. 
doi:10.1016/j.jprot.2011.01.006. 
[51] A. Taichrib, M. Pioch, C. Neusüß, Multivariate statistics for the differentiation of erythropoietin 
preparations based on intact glycoforms determined by CE-MS, Anal. Bioanal. Chem. 403 (2012) 
797–805. doi:10.1007/s00216-012-5924-8. 
[52] A. Taichrib, M. Pioch, C. Neusüß, Toward a screening method for the analysis of small intact 
proteins by CE-ESI-TOF MS: CE and CEC, Electrophoresis 33 (2012) 1356–1366. 
doi:10.1002/elps.201100620. 
[53] R. Haselberg, G.J. de Jong, G.W. Somsen, Low-Flow Sheathless Capillary Electrophoresis–Mass 
Spectrometry for Sensitive Glycoform Profiling of Intact Pharmaceutical Proteins, Anal. Chem. 85 
(2013) 2289–2296. doi:10.1021/ac303158f. 
[54] D. Thakur, T. Rejtar, B.L. Karger, N.J. Washburn, C.J. Bosques, N.S. Gunay, Z. Shriver, G. 
Venkataraman, Profiling the Glycoforms of the Intact α Subunit of Recombinant Human Chorionic 
Gonadotropin by High-Resolution Capillary Electrophoresis−Mass Spectrometry, Anal. Chem. 81 
(2009) 8900–8907. doi:10.1021/ac901506p. 
[55] J. Camperi, B. De Cock, V. Pichon, A. Combes, J. Guibourdenche, T. Fournier, Y. Vander 
Heyden, D. Mangelings, N. Delaunay, First characterizations by capillary electrophoresis of human 
Chorionic Gonadotropin at the intact level, Talanta. 193 (2019) 77–86. 
doi:10.1016/j.talanta.2018.09.095. 
[56] J. Kelly, S. Locke, L. Ramaley, P. Thibault, Development of electrophoretic conditions for the 
characterization of protein glycoforms by capillary electrophoresis—electrospray mass spectrometry, 
J. Chromatogr. A. 720 (1996) 409–427. doi:10.1016/0021-9673(94)01197-4. 
[57] R. Haselberg, V. Brinks, A. Hawe, G.J. de Jong, G.W. Somsen, Capillary electrophoresis-mass 
spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals, Anal. 
Bioanal. Chem. 400 (2011) 295–303. doi:10.1007/s00216-011-4738-4. 
[58] D.R. Bush, L. Zang, A.M. Belov, A.R. Ivanov, B.L. Karger, High Resolution CZE-MS 
Quantitative Characterization of Intact Biopharmaceutical Proteins: Proteoforms of Interferon-β1, 
Anal. Chem. 88 (2016) 1138–1146. doi:10.1021/acs.analchem.5b03218. 
[59] R. Haselberg, T. De Vijlder, R. Heukers, M.J. Smit, E.P. Romijn, G.W. Somsen, E. Domínguez-
Vega, Heterogeneity assessment of antibody-derived therapeutics at the intact and middle-up level by 
low-flow sheathless capillary electrophoresis-mass spectrometry, Anal. Chim. Acta. 1044 (2018) 181–
190. doi:10.1016/j.aca.2018.08.024. 
[60] A.M. Belov, L. Zang, R. Sebastiano, M.R. Santos, D.R. Bush, B.L. Karger, A.R. Ivanov, 
Complementary middle-down and intact monoclonal antibody proteoform characterization by 
capillary electrophoresis-mass spectrometry, Electrophoresis 39 (2018) 2069-2082. 
doi:10.1002/elps.201800067. 
[61] V. Sanz-Nebot, E. Balaguer, F. Benavente, C. Neusüß, J. Barbosa, Characterization of transferrin 
glycoforms in human serum by CE-UV and CE-ESI-MS, Electrophoresis 28 (2007) 1949–1957. 
doi:10.1002/elps.200600648. 
34 
[62] I. Kohler, M. Augsburger, S. Rudaz, J. Schappler, New insights in carbohydrate-deficient 
transferrin analysis with capillary electrophoresis–mass spectrometry, Forensic Sci. Int. 243 (2014) 
14–22. doi:10.1016/j.forsciint.2014.03.014. 
[63] A. Puerta, J. Bergquist, Development of a CE-MS method to analyze components of the potential 
biomarker vascular endothelial growth factor 165, Electrophoresis 30 (2009) 2355–2365. 
doi:10.1002/elps.200800738. 
[64] C.A. Lucy, A.M. MacDonald, M.D. Gulcev, Non-covalent capillary coatings for protein 
separations in capillary electrophoresis, J. Chromatogr. A. 1184 (2008) 81–105. 
doi:10.1016/j.chroma.2007.10.114. 
[65] E.A.S. Doherty, R.J. Meagher, M.N. Albarghouthi, A.E. Barron, Microchannel wall coatings for 
protein separations by capillary and chip electrophoresis, Electrophoresis 24 (2003) 34–54. 
doi:10.1002/elps.200390029. 
[66] S. Tengattini, E. Dominguez-Vega, C. Temporini, M. Terreni, G.W. Somsen, Monitoring 
antigenic protein integrity during glycoconjugate vaccine synthesis using capillary electrophoresis-
mass spectrometry, Anal. Bioanal. Chem. 408 (2016) 6123-6132. doi:10.1007/s00216-016-9723-5. 
[67] S. Arizaga-Rodriguez, E. blanco-Gonzalez, G. alvarez-Lamas, M. Montes-Bayon, A. Sanz-
Medel, Detection of transferrin isoforms in human serum: comparison of UV and ICP-MS detection 
after CZE and HPLC separations, anal. Bioanal. Chem. 383 (2005) 390-397. doi:10.1007/s00216-005-
3217-1. 
[68] K. Jooβ, J. Hühner, S. Kiessig, B. Moritz, C. Neusüβ, Two-dimensional capillary zone 
electrophoresis-mass spectrometry for the characterization of intact monoclonal antibody charge 
variants, including deamidation products, Anal. Bioanal. Chem. 409 (2017) 6057-6067. 
Doi:10.1007/s00216-017-0542-0. 
[69] A. Stolz, K. Jooβ, O. Höcker, J. Römer, J. Schlecht, C. Neusüβ, Recent advances in capillary 
electrophoresis-mass spectrometry: instrumentation, methodology and applications, Electrophoresis 40 
(2019) 79-112. doi:10.1002/elps.201800331. 
[70] E.A. Redman, N.G. Batz, J.S. Mellors, J.M. Ramsey, Integrated microfluidic capillary 
electrophoresis-electrospray ionization devices with online MS detection for the separation and 
characterization of intact monoclonal antibody variants, Anal. Chem. 87 (2015) 2264-2272. 
doi:10.1021/ac503964j. 
[71] J. Hühner, M. Lämmerhofer, C. Neusüß, Capillary isoelectric focusing-mass spectrometry: 
Coupling strategies and applications: CE and CEC, Electrophoresis 36 (2015) 2670–2686. 
doi:10.1002/elps.201500185. 
[72] L. Yang, Q. Tang, A.K. Harrata, C.S. Lee, Capillary isoelectric focusing-electrospray ionization 
mass spectrometry for transferrin glycoforms analysis, Anal. Biochem. 243 (1996) 140-149. 
[73] L. Wang, T. Bo, Z. Zhang, G. Wang, W. Tong, D.D.Y. Chen, High resolution capillary isoelectric 
focusing mass spectrometry analysis of peptides, proteins, and monoclonal antibodies with flow-
through microvial interface, Anal. Chem. 90 (2018) 9495-9503. Doi:10.1021/acs.analchem.8b02175. 
[74] C. Montealegre, C. Neusüβ, Coupling imaged capillary isoelectric focusing with mass 
spectrometry using a nanoliter valve, Electrophoresis 39 (2018) 1151-1154. 
Doi:10.1002/elps.201800013. 
[75] K. Shimura, Recent advances in IEF in capillary tubes and microchips, Electrophoresis 30 (2009) 
11–28. doi:10.1002/elps.200800615. 
[76] K. Sandra, I. Vandenheede, P. Sandra, Modern chromatographic and mass spectrometric 
techniques for protein biopharmaceutical characterization, J. Chromatogr. A. 1335 (2014) 81–103. 
doi:10.1016/j.chroma.2013.11.057. 
35 
[77] J.J. Kirkland, S.A. Schuster, W.L. Johnson, B.E. Boyes, Fused-core particle technology in high-
performance liquid chromatography: An overview, J. Pharm. Anal. 3 (2013) 303–312. 
doi:10.1016/j.jpha.2013.02.005. 
[78] S. Fekete, R. Berky, J. Fekete, J.-L. Veuthey, D. Guillarme, Evaluation of recent very efficient 
wide-pore stationary phases for the reversed-phase separation of proteins, J. Chromatogr. A. 1252 
(2012) 90–103. doi:10.1016/j.chroma.2012.06.066. 
[79] S. Fekete, R. Berky, J. Fekete, J.-L. Veuthey, D. Guillarme, Evaluation of a new wide pore core–
shell material (Aeris
TM
 WIDEPORE) and comparison with other existing stationary phases for the 
analysis of intact proteins, J. Chromatogr. A. 1236 (2012) 177–188. 
doi:10.1016/j.chroma.2012.03.018. 
[80] S. Fanali, An overview to nano-scale analytical techniques: Nano-liquid chromatography and 
capillary electrochromatography: CE and CEC, Electrophoresis 38 (2017) 1822–1829. 
doi:10.1002/elps.201600573. 
[81] S. Fekete, D. Guillarme, Ultra-high-performance liquid chromatography for the characterization 
of therapeutic proteins, TrAC Trends Anal. Chem. 63 (2014) 76–84. doi:10.1016/j.trac.2014.05.012. 
[82] R. Zhu, L. Zacharias, K.M. Wooding, W. Peng, Y. Mechref, Glycoprotein Enrichment Analytical 
Techniques, in: Methods Enzymol., Elsevier, 2017: pp. 397–429. doi:10.1016/bs.mie.2016.11.009. 
[83] M.K. Parr, O. Montacir, H. Montacir, Physicochemical characterization of biopharmaceuticals, J. 
Pharm. Biomed. Anal. 130 (2016) 366-389. doi:10.1016/j.jpba.2016.05.028. 
[84] S. Fekete, A. Beck, E. Wagner, K. Vuignier, D. Guillarme, Adsorption and recovery issues of 
recombinant monoclonal antibodies in reversed-phase liquid chromatography, J. Sep. Sci. 38 (2015) 
1–8. doi:10.1002/jssc.201400996. 
[85] S. Fekete, A. Beck, E. Wagner, K. Vuignier, D. Guillarme, Adsorption and recovery issues of 
recombinant monoclonal antibodies in reversed-phase liquid chromatography, J. Sep. Sci. 38 (2015) 
1–8. doi:10.1002/jssc.201400996. 
[86] A. Harazono, N. Hashii, R. Kuribayashi, S. Nakazawa, N. Kawasaki, Mass spectrometric 
glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS, J. 
Pharm. Biomed. Anal. 83 (2013) 65–74. doi:10.1016/j.jpba.2013.04.031. 
[87] H. Toll, P. Berger, A. Hofmann, A. Hildebrandt, H. Oberacher, H.P. Lenhof, C.G. Huber, 
Glycosylation patterns of human chorionic gonadotropin revealed by liquid chromatography-mas 
spectrometry and bioinformatics, Electrophoresis 27 (2006) 2734-2746. Doi:10.1002/elps.200600022. 
[88] J. Camperi, A. Combes, J. Guibourdenche, D. Guillarme, V. Pichon, T. Fournier, N. Delaunay, 
An attempt to characterize the human Chorionic Gonadotropin protein by reversed phase liquid 
chromatography coupled with high-resolution mass spectrometry at the intact level, J. Pharm. Biomed. 
Anal. (2018). doi:10.1016/j.jpba.2018.07.056. 
[89] T. Cabras, R. Boi, E. Pisano, F. Lavarone, C. Fanali, S. Nemolato, G. Faa, M. Castagnola, I. 
Messana, HPLC-ESI-MS and MS/MS structural characterization of multifucosylated N-glycoforms of 
the basic proline-rich protein IB-8a CON1
+
 in human saliva, J. Sep. Sci. 35 (2012) 1079-1086. 
doi:10.1002/jssc.201101066. 
[90] H.S. Gadgil, G.D. Pipes, T.M. Dillon, M.J. Treuheit, P.V. Bondarenko, Improving mass accuracy 
of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry 
of intact antibodies, J. Am. Soc. Mass Spectrom. 17 (2006) 867-872. 
Doi:10.1016/j.jasms.2006.02.023. 
[91] E. Wagner-Rousset, A. Bednarczyk, M.C. Bussat, O. Colas, N. Corvaïa, C? Schaeffer, A. Van 
Dorsselaer, A. Beck, The way forward, enhanced characterization of therapeutic antibody 
36 
glycosylation: comparison of three level mass spectrometry-based strategies, J. Chromatogr. B 872 
(2008) 23-37. Doi:10.1016/j.jchromb.2008.03.032. 
[92] S. Sinhya, G. Pipes, E.M. Topp, P.V. Bondarenko, M.J. Treuheit, H.S. Gadgil, Comparison of LC 
and LC/MS methods for quantifying N-glycosylation in recombinant IgGs, J. Am. Soc. Mass 
Spectrom. 19 (2008) 1643-1654, doi:10.1016/j.jasms.2008.07.004. 
[93] R.F. Carney, E. Dremina, J.L. Snyder, Z. Lakos, The role of liquid chromatography-mass 
spectrometry in the characterization of therapeutic monoclonal antibodies, Current Trends Mass 
Spectrom. 14 (2016) 42-52. 
[94] O. Montacir, H. Montacir, M. Eravci, A. Springer, S. Hinderlich, A. Saadati, M.K. Parr, 
Comparability study of rituximab originator and follow-on biopharmaceutical, J. Pharm. Biomed. 
Anal. 140 (2017) 239-251. doi:10.1016/j.jpba.2017.03.029. 
[95] J.F.M. Jacobs, R.A. Wevers, D.J. Lefeber, M. van Scherpenzeel, Fast, robust and high-resolution 
glycosylation profiling of intact monoclonal IgG antibodies using nanoLC-chip-QTOF, Clin. Chim. 
Acta. 461 (2016) 90–97. doi:10.1016/j.cca.2016.07.015. 
[96] C. Regl, T. Wohlschlager, W. Esser-Skala, I. Wagner, M. Samonig, J. Holzmann, C.G. Huber, 
Dilute-and-shoot analysis of therapeutic monoclonal antibody variants in fermentation broth: a method 
capability study, MABS (2018). doi:10.1080/19420862.2018.1563034. 
[97] L.E. Kilpatrick, E.L. Kilpatrick, Optimizing high-resolution mass spectrometry for the 
identification of low-abundance post-translational modifications of intact proteins, J. Proteome Res. 16 
(2017) 3255-3265. Doi:10.1021/acs.jproteome.7b00244. 
[98] I. Loke, N.H. Packer, M. Thaysen-Andersen, Complementary LC-MS/MS-based N-glycans, N-
glycopeptide, and intact N-glycoprotein profiling reveals unconventional Asn71-glycosylation of 
human neutrophil cathepsin G, Biomol. 5 (2015) 1832-1854. doi:10.3390/biom5031832. 
[99] B. Manconi, T. Cabras, M. Sanna, V. Piras, B. Liori, E. Pisano, F. Lavarone, F. Vincenzoni, M. 
Cordaro, G. Faa, M. Castagnola, I. Messana, N- and O-linked glycosylation site profiling of the human 
basic salivary proline-rich protein 3M, J. Sep. Sci. 39 (2016) 1987-1997. doi:10.1002/jssc.201501306. 
[100] M. van Scherpenzeel, G. Steenbergen, E. Morava, R.A. Wevers, D.J. Lefeber, High-resolution 
mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the 
congenital disorders of glycosylation, Transl. Res. 166 (2015) 639-649.e1. 
doi:10.1016/j.trsl.2015.07.005. 
[101] N. Abu Bakar, N.C. Voermans, T. Marquardt, C. Thiel, M.C.H. Janssen, H. Hansikova, E. 
Crushell, J. Sykut-Cegielska, F. Bowling, L. Mørkrid, J. Vissing, E. Morava, M. van Scherpenzeel, 
D.J. Lefeber, Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in 
phosphoglucomutase-I deficiency, Transl. Res. (2018). doi:10.1016/j.trsl.2018.04.008. 
[102] M.D. Zolodz, J.T. Herberg, H.E. Narepekha, E. Raleigh, M.R. Farber, R.L. Dufield, D.M. 
Boyle, Separation by hydrophobic interaction chromatography and structural determination by mass 
spectrometry of mannosylated glycoforms of a recombinant transferrin-exendin-4 fusion protein from 
yeast, J. Chromatogr. A 1217 (2010) 225-234. Doi:10.1016/j.chroma.2009.10.057. 
[103] B. Buszewski, S. Noga, Hydrophilic interaction liquid chromatography (HILIC)—a powerful 
separation technique, Anal. Bioanal. Chem. 402 (2012) 231–247. doi:10.1007/s00216-011-5308-5. 
[104] P.J. Boersema, S. Mohammed, A.J.R. Heck, Hydrophilic interaction liquid chromatography 
(HILIC) in proteomics, Anal. Bioanal. Chem. 391 (2008) 151–159. doi:10.1007/s00216-008-1865-7. 
[105] P. Jandera, Stationary and mobile phases in hydrophilic interaction chromatography: a review, 
Anal. Chim. Acta. 692 (2011) 1–25. doi:10.1016/j.aca.2011.02.047. 
[106] A. Périat, I.S. Krull, D. Guillarme, Applications of hydrophilic interaction chromatography to 
amino acids, peptides, and proteins, J. Sep. Sci. 38 (2015) 357-367. doi:10.1002/jssc.201400969. 
37 
[107] V. D’atri, E. Dumont, I. Vandenheede, D. Guillarme, P. Sandra, K. Sandra, Hydrophilic 
interaction chromatography for the characterization of therapeutic monoclonal antibodies at protein, 
peptide, and glycan levels, LC-GC Eur. 30 (2017) 424-434.  
[108] M. Wuhrer, A.R. de Boer, A.M. Deelder, Structural glycomics using hydrophilic interaction 
chromatography (HILIC) with mass spectrometry, Mass Spectrom. Rev. 28 (2009) 192–206. 
doi:10.1002/mas.20195. 
[109] M.R. Gama, R.G. da Costa Silva, C.H. Collins, C.B.G. Bottoli, Hydrophilic interaction 
chromatography, TrAC Trends Anal. Chem. 37 (2012) 48–60. doi:10.1016/j.trac.2012.03.009. 
[110] H.P. Nguyen, K.A. Schug, The advantages of ESI-MS detection in conjunction with HILIC 
mode separations: Fundamentals and applications, J. Sep. Sci. 31 (2008) 1465–1480. 
doi:10.1002/jssc.200700630. 
[111] A. Periat, S. Fekete, A. Cusumano, J.-L. Veuthey, A. Beck, M. Lauber, D. Guillarme, Potential 
of hydrophilic interaction chromatography for the analytical characterization of protein 
biopharmaceuticals, J. Chromatogr. A. 1448 (2016) 81–92. doi:10.1016/j.chroma.2016.04.056. 
[112] S. Tengattini, E. Domínguez-Vega, C. Temporini, T. Bavaro, F. Rinaldi, L. Piubelli, L. 
Pollegioni, G. Massolini, G.W. Somsen, Hydrophilic interaction liquid chromatography-mass 
spectrometry as a new tool for the characterization of intact semi-synthetic glycoproteins, Anal. Chim. 
Acta. 981 (2017) 94–105. doi:10.1016/j.aca.2017.05.020. 
[113] E. Domínguez-Vega, S. Tengattini, C. Peintner, J. van Angeren, C. Temporini, R. Haselberg, G. 
Massolini, G.W. Somsen, High-resolution glycoform profiling of intact therapeutic proteins by 
hydrophilic interaction chromatography-mass spectrometry, Talanta. 184 (2018) 375–381. 
doi:10.1016/j.talanta.2018.03.015. 
[114] Z. Zhang, Z. Wu, M.J. Wirth, Polyacrylamide brush layer for hydrophilic interaction liquid 
chromatography of intact glycoproteins, J. Chromatogr. A. 1301 (2013) 156–161. 
doi:10.1016/j.chroma.2013.05.076. 
[115] M. Alvarez, G. Tremintin, J. Wang, M. Eng, Y.H. Kao, J. Jeong, V.T. Ling, O.V. Borisov, On-
line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry 
operating in a two-dimensional format, Anal. Biochem. 419 (2011) 17-25. doi: 
10.1016/j.ab.2011.07.033. 
[116] E. Farsang, A. Murisier, K. Horvath, O. Colas, A. Beck, D. Guillarme, S. Fekete, Optimization 
of MS-compatible mobile phase for IEX separation of monoclonal antibodies, LC-GC Eur. 32 s5 
(2019) 29-34. 
[117] B. chen, Y. Peng, S.G. Valeja, L. Xiu, A.J. Alpert, Y. Ge, Online hydrophobic interaction 
chromatography-mass spectrometry for top-down proteomics, Anal. Chem. 88 (2016) 1885-1891. 
doi:10.1021/acs.analchem.5b04285. 
[118] B. Chen, Z. Lin, A.J. Alpert, C. Fu, Q. Zhang, W.A. Pritts, Y. Ge, Online hydrophobic 
interaction chromatography-mass spectrometry for the analysis of intact monoclonal antibodies, Anal. 
Chem. 90 (2018) 7135-7138. Doi:10.1021/acs.analchem.8b01865. 
[119] I. Vandenheede, P. Sandra, K. Sandra, Denaturing and native size-exclusion chromatography 
coupled to high-resolution mass spectrometry for detailed characterization of monoclonal antibodies 
and antibody-drug conjugates, LC-GC Eur. 32 (2019) 304-312. 
[120] R. Kuribayashi, N. Hashii, A. Harazono, N. Kawasaki, Rapid evaluation for heterogeneities in 
monoclonal antibodies by liquid chromatography/mass spectrometry with a column-switching system, 
J. Pharm. Biomed. Anal. 67-68 (2012) 1-9. doi:10.1016/j.jpba.2012.04.005. 
38 
[121] M. Gafvels, P. Bengtson, A fast semi-quantitative LC-MS method for measurement of intact 
apolipoprotein A-I reveals novels proteoforms in serum, Clin. Chim. Acta 442 (2015) 87-95. 
doi:10.1016/j.cca.2015.01.011. 
[122] K. Sandra, M. Steenbeke, I. Vandenheede, G. Vanhoenacker, P. Sandra, The versatility of heart-
cutting and comprehensive two-dimensional liquid chromatography in monoclonal antibody clone 
selection, J. Chromatogr. A 1523 (2017) 283-292. doi:10.1016/j.chroma.2017.06.3052. 
  
 39 
Table 1: CZE-MS for the characterization of proteins glycosylation at the intact level 
Protein 
Capillary 
coating and 
dimensions 
EOF BGE 
MS 
analyzer 
Interface, sheath liquid, flow 
Number of peaks in 
CE (migration time 
range) 
Number of 
isoforms (I) 
/ glycoforms 
(G) 
Objectives Ref. 
AGP 
(1) PB or (2) PA 
100 cm x 50 µm 
A 
1 M AA, 20% 
MeOH pH 2.4 
TOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
5 (18-22 min) 21 G 
method 
development, 
identification 
of glycoforms 
[38] 
AGP 
DMA-EPyM,  
65 cm x 50 µm 
A 1 M AA pH 2.4 qTOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
9 (6-10 min) 150 I 
isoform 
profiling 
[39,40] 
AGP 
PA or DMA-
EPyM,  
65 cm x 50 µm 
0 or 
A 
1 M AA pH 2.4 qTOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
8 (7.5-11 min)  
Sample 
handling 
optimization 
[41] 
Ag85B 
PB-DS-PB 
90 cm x 50 µm 
A 1.5 M AA pH 2.3 qTOF 
SL (co-axial), 0.1% FA in IPA-
H2O (1/1) 
3 µl min-1 
- 4 G 
production 
monitoring 
[42] 
AT 
PVA 
100 cm x 50 µm. 
0 1 M AA, 4 M urea qIT 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
3 µl min-1 
5 (60-75 min) 7 G 
method 
development, 
identification 
of glycoforms 
[43] 
BF 
(1) PB or (2) PA 
100 cm x 50 µm 
A 
1 M AA, 20% 
MeOH pH 2.4 
TOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
6 (16-21 min) 14 G 
method 
development, 
identification 
of glycoforms 
[38] 
 40 
BMP-2 
LPA 
65-68 cm x 50 
µm 
0 
50 mM β-Alanine + 
AA pH 3.5 
Q 
SL (co-axial), 0.1% FA in 
MeOH-H2O (75/25) 
3 µl min-1 
4 (15-25 min) 15 G 
isoform 
profiling 
[44] 
EPO 
PB 
101 cm x 50 µm 
A 
1 M AA, 20% 
MeOH pH 2.4 
TOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
7 (16-21 min) 135 I (44 G) 
method 
development, 
isoform 
profiling 
[45] 
EPO 
Ionene 
78 or 98 cm x 50 
µm 
A 
10 mM NH4Ac pH 
4.8 
IT 
SL (co-axial), 10 mM NH4Ac 
pH 4.8-ACN (1/1) 
10 µl min-1 
7 (13-15 min)  
isoform 
separation 
[46] 
EPO 
PB 
60 cm x 50 µm 
A 
1 M AA, 20% 
MeOH pH 2.4 
TOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
7 (5.5-7 min) > 50 G 
isoform 
profiling 
[47] 
EPO 
(1) PB or (2) 
LPA, (1) 80 cm 
or (2) 100 cm x 
50 µm 
A or 
0 
(1) 1 M AA, 20% 
MeOH pH 2.4 
(2) 2 M AA 
pH 2.1 
TOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
(1) 6 (16-18.5 min) 
(2) 10 (20-29 min) 
64 G 
identification 
of glycoforms 
[48] 
EPO 
(1) PA or (2) HR, 
80 cm x 50 µm 
0 or 
A 
2 M AA pH 2.1 IT 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
3.3 µl min-1 
(1) 1 (20-30 min) 
(2) 1 (21-30 min) 
6 G 
isoform 
profiling 
[49] 
EPO 
PA 
60 cm x 50 µm 
0 1 M AA pH 2.4 qTOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
4 µl min-1 
 > 10 (9-14 min) 
 
> 7 G  
identification 
of glycoforms 
[50] 
EPO 
PA 
60 cm x 50 µm. 
0 1 M AA pH 2.4 qTOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
3 µl min-1 
20 (10-15 min) 10 G 
statistical 
comparison of 
glycoprofiles 
[51] 
 41 
EPO 
PA 
60 cm x 50 µm 
0 0.5 M AA pH 4.2 qTOF 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
3 µl min-1 
< 10 (10-20 min) 8 G 
method 
development, 
statistical 
comparison of 
glycoprofiles 
[52] 
EPO 
PA 
100 cm x 30 µm 
0 2 M AA pH 2.1 TOF CESI 23 (32-46 min) 250 I (74 G) 
identification 
of glycoforms 
[53] 
hCGα 
PVA 
20 cm x 50 µm 
0 2% AA pH 2.5 LTQ-FT 
SL (T junction), 2% AA in 
ACN-H2O (8/2) 
- 
10 (8-16 min) 60 G 
identification 
of glycoforms 
[54] 
hCG 
No coating 
60 cm x 50 µm 
0 
0.8 M FA, 0.8 M 
AA, 20% MeOH pH 
2.2 
TQ 
SL (co-axial), 0.1% FA in 
MeOH-H2O (1/1) 
6 µl min-1 
8 (3-5 min) - 
method 
development, 
isoform 
profiling 
[55] 
HRP 
PB and PEG 
110 cm x 50 µm 
A 2 M FA pH 2.6 TQ 
SL (T junction), 0.2% FA in 
MeOH-H2O (25/75) 
5 µl min-1 
3 (21-24 min) 9 G 
method 
development, 
glycoform 
separation 
[56] 
IFN-β 
PA 
100 cm x 30 µm 
0 50 mM AA pH 3.0 TOF CESI 7 (29-32 min) 18 G 
identification 
of glycoforms 
[53] 
IFN-β 
PB-DS-PB 
80 cm x 50 µm 
A 50 mM AA pH 3.0 qTOF 
SL (co-axial), 0.5 % AA in IPA-
H2O (25/75) 
2 µl min-1 
11 (7-10 min) 10 G 
method 
development, 
identification 
of glycoforms 
[57] 
IFN-β 
PEI 
100 cm x 30 µm 
A 3% AA pH 2.5 
LTQ-
Orbitrap 
CESI - 138 I (15 G) 
identification 
of glycoforms 
[58] 
 42 
mAb 
Neutral OptiMS 
91 cm x 30 µm 
0 10% AA pH 2.2 qTOF CESI 3 (26-30 min) 18 I (8 G) 
identification 
of glycoforms 
[59] 
mAb 
M7C4I or PA 
- 
A or 
0 
0.2% FA in 10% IPA qOrbitrap CESI - 14 G 
identification 
of glycoforms 
[60] 
NESP 
(1) PA or (2) HR, 
80 cm x 50 µm 
0 or 
A 
2 M AA pH 2.1 IT 
SL (co-axial), 1% AA in IPA-
H2O (1/1) 
3.3 µl min-1 
(1) 3 (40-80 min) 
(2) 3 (14-19 min) 
3 G 
isoform 
profiling 
[49] 
RNase B 
PB and PEG 
110 cm x 50 µm 
A 2 M FA pH 2.6 TQ 
SL (T junction), 0.2% FA in 
MeOH-H2O (25/75) 
5 µl min-1 
5 (33-36 min) 
 
5 G 
method 
development, 
glycoform 
separation 
[56] 
RNase B 
LPA 
65-68 cm x 50 
µm 
0 
50 mM β-Alanine + 
AA pH 3.5 
Q 
SL (co-axial), 0.1% FA in 
MeOH-H2O (75/25) 
3 µl min-1 
5 (17-19 min) 
5 G 
 
isoform 
profiling 
[44] 
TB10.4 
PB-DS-PB 
90 cm x 50 µm 
A 1.5 M AA pH 2.3 qTOF 
SL (co-axial), 0.1% FA in IPA-
H2O (1/1) 
3 µl min-1 
- 14 G 
production 
monitoring 
[42] 
Tf 
PB-DS 
70 cm x 50 µm 
C 
25 mM NH4Ac pH 
8.5 
TOF 
SL (co-axial), 0.5% FA in 
MeOH-H2O (9/1) 
2 µl min-1 
4 (13-15 min) 4 G serum analysis [61] 
Tf 
PB-DS 
129 cm x 50 µm 
C 
20 mM NH4Ac pH 
8.5 
TOF 
SL (co-axial), 5% FA in IPA-
H2O (1/1) 
4 µl min-1 
1 (24-26 min) 2 G 
method 
development 
[62] 
VEGF165 
Polyamine 
50 cm x 50 µm 
A 60 mM FA pH 3.0 TOF 
SL (co-axial), 90 mM AA in 
IPA-H2O (1/1) 
1 µl min-1 
7 (30-45 min) 19 I 
identification 
of glycoforms 
[63] 
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Abbreviations: AA, acetic acid; ACN, acetonitrile; AGP, α1-acid glycoprotein; AT, antithrombin; BF, bovine fetuin; BMP-2, bone morphogenetic protein-2; DMA-EpyM, 
acrylamide-pyroline methacrylate copolymer; DS, dextran sulfate; EPO, erythropoietin; FA, formic acid; G, glycoform; hCG, human chorionic gonadotropin; hCGα, human 
chorionic gonadotropin α-subunit; HRP, horse radish peroxidase; I, isoform; IFN-β, interferon-β-1a; IPA, isopropanol; IT, ion trap; LPA, linear polyacrylamide; LTQ, linear 
trap quadrupole; LTQ-FT, linear trap quadrupole-Fourier transform; NH4Ac, ammonium acetate; PA, polyacrylamide; PB, polybrene; PEG, polyethylene glycol; PEI, 
polyethylenimine; PVA, polyvinyl alcohol; Q, quadrupole; qIT, quadrupole ion trap; qTOF, quadrupole time-of-flight; RNase-B, ribonuclease B; Tf, transferrin; TOF, time-
of-flight; TQ, triple quadrupole; VEGF165, vascular endothelial growth factor 165. 
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Table 2: RPLC-MS for the characterization of protein glycosylation at the intact level 
Protein 
Analytical column  
(dimensions) 
Injection 
(µl, mg ml-1 
in media) 
Mobile phase 
Flow  
(µl min-1) 
T 
(°C) 
Number of peaks in LC  
(elution time range) 
MS 
analyzer 
Application Ref. 
EPO 
MonoCap C18 fast-flow  
(250 x 0.1 mm, 5 µm) 
-, 0.015 in 
H2O 
ACN-H2O  
+ 0.1% FA 
0.5  - 
1  
 (18.7–20.0 min) 
qTOF Quality control 
 
[86] 
hCG 
Home-made PS-DVB monolith 
(60 x 0.2 mm) 
- 
ACN-H2O  
+ 0.05% TFA 
2 50 4 IT 
Glycoform 
annotation 
[87] 
 
hCG  
Aeris WIDEPORE XB-C18 
(150 x 2.1 mm, 3.6 µm, 200 Å) 
5, 0.1 in H2O 
ACN-H2O  
+ 0.1% FA 
400 65 
rhCG: 12 
(24-36 min), uhCG: > 8 
(24-36 min) 
qTOF Quality control 
 
[88] 
IB-8a 
CON1+ 
Vydac C8 
(150 x 2.1 mm, 5  µm) 
- 
ACN-H2O  
+ 0.05% TFA 
300 - 1 (14.5-16 min) IT Diagnosis [89] 
mAb 
Zorbax 300SB-C8  
(50 x 1 mm, 3.5 µm, 300 Å) 
- 
ACN- n-propanol-
H2O- + 0.1% TFA 
50 75 - qTOF MW 
determination 
[90] 
mAb 
Zorbax 300SB-C8 
(30 x 2.1 mm, 3.5 µm, 300 Å) 
- 
n-propanol-H2O + 
0.02% TFA +  
1% FA 
250 60 - TOF 
Glycoform 
annotation 
[91] 
mAb 
Varian diphenyl  
(150 x 2 mm) 
- 
ACN-H2O  
 + 0.1% TFA 
200 75 - TOF 
mAbs 
comparison 
[92] 
mAb 
AdvanceBio RP-mAb diphenyl 
(100 x 2.1 mm, 3.5 µm) 
5-10, 2 in 
H2O  
ACN-n-propanol-
H2O + 0.05% TFA 
200 80 - qTOF 
Glycoform 
annotation 
[93] 
 45 
mAb 
BEH300  
(50 x 2.1 mm, 1.7 µm, 300 Å) 
3.5, 0.5 in 
0.05 M ABC 
pH 7 
ACN-H2O  
 + 0.1% FA 
200 80 - qTOF 
mAbs 
comparison 
[94] 
mAb 
C8-chip  
(43 mm x 75 μm) 
2, 1.0 in H2O 
ACN-H2O  
 + 0.1% FA  
 
0.3 
 
- 
 1  
(4-7 min) 
qTOF 
Quality control, 
diagnosis 
[95] 
mAb 
ProSwift RP-10R PS-DVB 
monolith (50 x 1 mm) 
- 
ACN-H2O  
+ 0.05% TFA 
200 70 - qOrbitrap Fermentation 
broth analysis 
[96] 
mAb, CRP, 
Tf, VDBP 
Bio Wide Pore C8 (150 x 2.1 mm, 3 
µm) or ProSwift RP-4H phenyl 
monolith (250 x 10 mm) 
-, - in H2O-
ACN + 0.02% 
TFA 
ACN-H2O  
+ 0.02% TFA 
200 60 - Orbitrap MS parameters 
optimization 
[97] 
nCG 
Proteocol C4Q 
(100 x 03 mm, 3 µm, 300 Å) 
1, -, - 
ACN-H2O  
+ 0.1% FA 
5 - - qTOF 
Glycoform 
identification 
[98] 
PRB3-M 
Vydac C8 
(150 x 2.1 mm, 5 µm) 
- 
ACN-H2O  
+ 0.05% TFA 
300 - 1 (17-19 min) IT 
Glycoform 
identification 
[99] 
Tf 
C8-chip 
(43 mm x 75 μm) 
2, - in Tris-
HCl pH 9  
ACN-H2O  
+ 0.1% FA  
0.4  - 
1  
(3.2-4 min) 
qTOF Diagnosis [100] 
Tf 
C8-chip 
(43 mm x 75 μm) 
2, - in Tris-
HCl pH 9  
ACN-H2O  
+ 0.1% FA  
0.4  - - qTOF Diagnosis [101] 
Tf-exendin-
4 fusion 
protein 
Zorbax 300SB-C18 
(150 x 4.6 mm, 3.5 µm) 
- 
ACN-H2O  
+ 0.1% TFA 
500 50 5 (14-19 min) qTOF 
MW 
determination 
[102] 
Abbreviations: ABC, ammonium bicarbonate; ACN, acetonitrile; CRP, C-reactive protein; EPO, erythropoietin; FA, formic acid; IT, ion trap; mAb, monoclonal antibody; 
nCG, Neutrophil cathepsin G; PRB3-M, proline-rich protein 3M; qTOF, quadrupole time-of-flight; Tf, transferrin; VDBP, vitamin D-binding protein. 
Table 3: HILIC-MS for the characterization of protein glycosylation at the intact level 
Protein 
Analytical column  
(L x i.d, dp, pore size) 
Injection 
(µl, mg ml-1, 
media) 
Mobile 
phase 
T 
(°C)  
MS 
analyze
r 
Number of 
peaks in 
LC (elution 
time range) 
Number of 
isoforms (I) 
/glycoforms 
(G) 
Application Ref. 
Ag85B  
TSKgel Amide-80  (150 × 2.0 mm, 3 μm, 80 Å)  
XBridge BEH Amide (150 × 3.0 mm, 2.5 μm, 130 Å) 
AdvanceBio Glycan Mapping amide (150 x 2.1 mm, 2.7 
μm, 300 Å) 
2, 0.5 in 
ACN/H2O 
/PBS 
 (50/25/25) 
ACN-H2O +  
0.05% TFA 
50 qTOF 
Ag85B: 8  
(13-17 min) 
TB10.4: 3  
(11-17 min) 
Ag85B: 8 I, 
7 G 
TB10.4: 3 I, 
2 G  
Method control 
for synthesis 
[112] 
EPO  
AdvanceBio Glycan Mapping amide  
(150 x 2.1 mm, 2.7 μm, 300 Å) 
2, 2.5 in H2O  
ACN-H2O +  
0.1% TFA 
EPO
: 60  
IFN: 
50 
qTOF 
EPO: < 15 
 (16-26 min) 
IFN: 12  
(2-10 min) 
EPO: 51 G 
IFN: 24 I, 12 
G 
Quality control [113] 
RNase B 
Lab-made Poly-acrylamide (30 x 2.1 mm, 700 nm)  
BEH Amide (30 x 2.1 mm, 1.7 μm)  
TSKgel Amide 80 (50 x 2.0 mm, 3 μm, 80 Å) 
-, -, in 
IPA/ACN/H2O 
(5/3/2) 
ACN-H2O + 
0.05% TFA 
+ 0.5% FA  
30 LTQ  
5  
(15-20 min) 
5 G 
Evaluation of a 
new stationary 
phase 
[114] 
 
Abbreviations: ACN, acetonitrile; EPO, erythropoietin; FA, formic acid; G, glycoform; I, isoform; IFN-β, interferon-β-1a; LTQ, linear trap quadrupole; PBS, phosphate 
buffer saline; qTOF, quadrupole time-of-flight; RNase-B, ribonuclease B; TFA, trifluoroacetic acid 
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